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ABSTRACT 
DNA repair protein (DNA-RP) overexpression in tumor cells has been reported to involve post-
translational protein stabilization mediated by the molecular chaperone, Heat shock protein 90 
(HSP90), thereby preventing proteasome-dependent degradation of these HSP90 “client” 
proteins. This overexpression of DNA-RP in a cancer-stage associated manner has also been 
correlated to chemotherapy resistance and poor overall prognosis. Hence, HSP90 inhibitors 
(HSP90i) have been heralded as cotherapy agents for cancer patients that have developed 
resistance to first-line treatments such as temozolomide (TMZ). Under conditions in which 
HSP90 function is blocked by HSP90i, HSP90 client proteins rapidly become polyubiquinated 
and undergo cytosolic degradation, resulting in sensitization of cancer cells to chemotherapy. We 
observed that HSP90i promote the proteasome-dependent degradation of a range of DNA repair 
client proteins, from which, we were able to define nine H-2Kb/Db-presented peptide epitopes 
that could be recognized by Type-1 CD8+ T cells after specific vaccination. When combined 
with an adoptive cell therapy (ACT) using anti-DNA-RP CD8+ T cells, HSP90i-cotreatment 
yielded superior anti-tumor efficacy against TMZ-resistant B16 melanomas established in the 
dermis of syngenic C57BL/6 mice. 
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v 
Innovation. This is the first study to focus on the use of HSP90i to conditionally promote the 
degradation and subsequent presentation of DNA-RP-derived peptides in MHC class I 
complexes, allowing for improved recognition of chemotherapy-refractory tumor cells by the 
adaptive (T cell) immune system in vitro and in vivo.  
Public health significance. Melanoma is the deadliest form of skin cancer, with increasing 
incidence worldwide. This study defines a novel approach that may be translated into the clinic 
for the treatment of patients with advanced-stage melanomas or alternate chemotherapy-resistant 
forms of cancer. This approach could be readily combined with a range of synergistic 
immunotherapies as a novel first- or second-line treatment option for patients that have 
previously developed (genotoxic or targeted) therapy-specific resistance. 
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1.0  INTRODUCTION 
1.1 MELANOMA OVERVIEW 
Melanoma is the deadliest form of skin cancer. It has steadily increased in incidence worldwide 
over the past several decades. Even though it is not the most common type of skin cancer, 
melanoma contributes to approximately 75% of skin cancer-related deaths annually ( Siegel et 
al., 2013; Siegel et al., 2016). Melanoma is a malignancy that evolves from melanocytes, skin 
cells that make the pigment, melanin. Melanoma often originates from a benign mole (also called 
a nevus) and can be identified by morphometric asymmetry, uneven borders, the presence of 
more than one color in the lesion, a diameter larger than ¼ inch and constant evolution over 
time; often referred to as the “ABCDE” rule for skin cancer diagnosis. A biopsy is recommended 
to be performed for diagnostic purposes on any suspicious lesion identified upon routine 
inspection of the skin (Guida et al., 2012). However, it is important to note that while most 
melanomas occur in the skin, there are instances for melanoma developing in mucosal surfaces 
and the uveal tract as well. In the past, melanomas have been divided into different subtypes 
based on their site of origin; i.e.,  cutaneous (skin), uveal (eye) and mucosal (lungs, gut, 
reproductive organs; Acquaviva et al., 2014). These three melanoma types differ in their 
etiology, geographic incidence distribution and clinical behaviors. Cutaneous melanoma occurs 
in the skin and is the most common type of melanoma. Cutaneous melanomas can be divided 
into four types based on histologic growth patterns; these are superficial spreading melanoma, 
An alphabetical list of abbreviations is provided in Appendix A 
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nodular melanoma, acral lentiginous melanoma and lentigo melanoma. Uveal melanoma is a rare 
form of melanoma that occurs in the eye (Jewell et al., 2010). 
Metastases of cutaneous melanomas can be segregated into three types based on their 
location relative to the primary lesion, i.) local metastasis, when a second lesion occurs within 2 
cm of a primary tumor, ii.) regional metastasis, when the secondary lesion is farther than 2 cm 
from the primary tumor, but is in the same anatomic region of the body, and iii.) distant 
metastasis, where the secondary lesion is identified in a different region of the body than the 
primary tumor (Maverakis et al., 2015). 
Despite melanoma representing one of the few cancers whose incidence has gone up 
dramatically over the last five decades, therapeutic advances capable of providing durable 
benefits to patients with melanoma remain limited. This increase in the incidence of melanoma 
and the lack of consensus curative treatment options for afflicted patients denotes a significant 
public health concern (Ha et al., 2011). 
1.2 MELANOMA PUBLIC HEALTH OVERVIEW 
UV exposure is a key risk factor in the development of melanoma, and geographic locations in 
which individuals reside are predictive of both the degree of UV exposure and relative melanoma 
incidence, with Australia currently having the highest melanoma incidence per capita in the 
world (Stecklein et al., 2012). Genetics also strongly influences the distribution of melanoma 
incidence. Lighter-skinned individuals have a much higher incidence rate of developing 
melanoma in comparison to their darker skinned counterparts, with a 3-7% annual increase in 
incidence of this disease amongst Caucasians (Che et al., 2013). The American Cancer Society 
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estimates that there will be 76,380 new cases of cutaneous melanoma diagnosed in 2016, with 
10,130 deaths expected in the US from this disease. Melanoma is the 6th most common type of 
cancer in the US (at 4.5% of all new cancer cases reported in the US). Melanoma occurs more 
commonly in men than women overall, however, before age 50, incidence is higher in women 
than men. Strikingly, after age 65, the rates of melanoma incidence in men are double those 
observed for women, and by age 80, they are tripled for men vs. women. The gender-linked 
disease incidence profile may be due to differences in changing patterns of occupational and 
recreational exposure to ultraviolet radiation by men vs. women as they age. The median age at 
diagnosis for melanoma is 63 and the median age for death amongst those afflicted with this 
disease is 69. Notably, the earlier a person is diagnosed with melanoma, the better their chances 
for 5 year survival (Schmidt-Ullrich et al., 2003; Dote et al., 2006; Ko et al., 2012; Siegel et al., 
2016). 
1.3 CURRENT THERAPIES FOR MELANOMA 
Common therapies for patients with melanoma that are currently applied in the clinic include 
surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy. 
1.3.1 Surgery 
When melanoma is localized and limited to a particular site of the body, surgery is an obvious 
first choice of treatment intervention. It is also used as a palliative treatment option when the 
cancer has metastasized to lungs or brain to relieve pain and to increase overall patient survival 
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(Younes et al., 2013). Surgery requires careful attention to disease margins and doesn’t work 
well as a single modality when metastatic disease is suspected, since it is hard to identify and 
remove microscopic metastases. Surgery is usually used prior to targeted therapy or 
immunotherapy as a means to “de-bulk” patients and to minimize the absolute number of tumor 
cells that must be directly impacted by the chosen subsequent immunotherapy (Maverakis et al., 
2015). 
1.3.2 Radiation Therapy (RT)  
Radiation is usually used as an adjunct therapy to alternate systemic therapies including 
cytotoxic chemotherapy, immunotherapy or combination approaches (Bhatia et al., 2009; 
Maverakis et al., 2015). Radiotherapy is a reasonable option for palliation; it was proved 
effective on melanoma patients with non-CNS metastasis, with complete resolution in 9% of 
cases and partial improvement in 75% of patients treated with a median dose of 30 Gy (Olivier et 
al., 2007). 
1.3.3 Chemotherapy 
Conventional cytotoxic chemotherapy has been used to treat melanoma for over 30 years. The 
two most commonly used chemotherapy drugs for melanoma patients are the alkylating agents, 
dacarbazine and temozolomide (TMZ) (Schindler & Postow, 2014). Although dacarbazine is 
FDA-approved for the treatment of melanoma, both agents seem to have similar efficacy with 
respect to patient overall survival, progression-free survival and quality-of-life benefit. Notably, 
TMZ has an additional benefit of being delivered orally, with the agent readily penetrating the 
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blood-brain barrier to truly provide systemic impact in treated patients. However, neither drug 
has been demonstrated to provide an overall survival benefit when evaluated in randomized 
clinical trials, requiring them to now be used in combination approaches (Middleton et al., 2000; 
Quirt et al., 2007). 
1.3.4 Targeted Therapy 
Activation of the mitogen-activated protein kinase (MAPK) pathway has become an oncogenic 
hallmark of melanoma, with approximately 50% of melanomas containing activating mutations.  
Activated MAPK pathway signaling leads to phosphorylation and activation of RAS, RAF, MEK 
and ERK, which impacts cellular differentiation, proliferation, survival and apoptosis of cells 
(Shah & Dronca, 2014). BRAF is commonly mutated amongst patients with melanoma (66% 
somatic missense mutations), with the BRAF(V600E) activating mutation most frequently 
detected amongst advanced-stage melanoma patients (Davies et al., 2002). This has made 
BRAF(V600E) protein an attractive therapeutic target in the melanoma setting. Vemurafenib, a 
specific synthetic small-molecule inhibitor of activated BRAF(V600E) has been evaluated 
extensively in clinical trials, with phase I/II trial results suggesting objective response rates 
(ORR) >50% for patients harboring BRAF(V600E) mutant melanomas. A phase III clinical trial 
comparing dacarbazine vs. vemurafenib in 675 melanoma patients with the BRAF(V600E) 
mutation supports the therapeutic superiority of vemurafenib based on extended overall survival. 
However, 38% of treated patients required dose de-escalation because of vemurafenib’s toxic 
effects (Chapman et al., 2011). These favorable clinical findings led to FDA approval of 
vemurafenib for patients with BRAF(V600E) mutant melanoma in 2011 (Schindler & Postow, 
2014). Dabrafenib, an alternate small-molecule BRAF inhibitor (BRAFi), with a similar activity 
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profile to vemurafenib, has also demonstrated clinical efficacy in patients with solid tumors, 
especially those with melanoma and untreated asymptomatic brain metastasis (Falchook et al., 
2012). The single-agent MEK inhibitor, Trametinib has also shown clinical activity against 
BRAF mutant melanomas (Johnson et al., 2015). 
However, despite such clinical benefits (with many patients exhibiting profound tumor 
regression), the vast majority of melanoma patients treated with BRAFi develop drug-refractory 
disease within 6-8 months of initiating treatment. Potential mechanisms of treatment-resistance 
include the activation of alternative oncogenic signaling pathways that reactivate downstream 
elements of the MAPK signaling pathway (Sullivan et al., 2013). 
1.3.5 Immunotherapy – Checkpoint Indicators 
Immunotherapy has been applied for the treatment of melanoma for decades, with high-dose 
interleukin (IL)-2 being FDA approved as a therapy option for patients with metastatic 
melanoma in 1998 (Maverakis et al., 2015).  Recent years have seen an explosion in the clinical 
use of novel immune checkpoint inhibitors that prevent the tumor-associated senescence of 
therapeutic T cells in patients. Interestingly, immunotherapies have been shown to elicit more 
durable anti-tumor benefits in patients when compared to targeted therapies, such as those 
implementing BRAFi (Johnson et al., 2015). Ipilimumab is a monoclonal antibody reactive 
against the cytotoxic T lymphocyte antigen 4 (CTLA4) molecule expressed by regulatory T cells 
(Treg) and some previously-activated T effector cells. Anti-CTLA4 antibody blocks the down-
regulation of T cell activation resulting from CTLA4-mediated signaling in Teff cells and limits 
the suppressive function of Treg, leading to overall enhancement of anti-tumor T cell 
effectiveness in vivo (Maverakis et al., 2015). In a phase III clinical study involving previously-
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treated metastatic melanoma patients, Ipilimumab improved overall survival when applied as 
either a monotherapy or when combined with a vaccine (targeting the melanoma-associated 
antigen PMEL)(Hodi et al., 2010). In 2011, the FDA approved Ipilimumab for the treatment of 
metastatic melanoma patients (regardless of BRAF mutational status) (Niezgoda et al., 2015). 
Tremelimumab, an alternate CTLA4 blocking antibody, did not result in an improvement in 
overall survival when compared to standard chemotherapy in a phase III clinical study, 
suggesting significant operational variability in this class of anti-cancer agents (Ribas et al., 
2013). 
The programmed cell death 1 receptor (PD-1) is expressed by T effector cells. When T 
cell PD-1 is bound by its ligand PD-L1, which is upregulated on the cell surface of melanoma 
cells and tumor-associated macrophages (TAM), T cells are induced to undergo apoptotic cell 
death (Maverakis et al., 2015).  Nivolumab and pembrolizumab are antagonist antibodies against 
PD-1 that have been recently evaluated as therapeutic agents in the melanoma setting. Patients 
with advanced-stage melanoma treated with nivolumab demonstrated improved median overall 
survival with high rates of tumor regression (Topalian et al., 2014). In another study, 28% of 
melanoma patients exhibited objective clinical responses after treatment with nivolumab 
(Topalian et al., 2012). In a phase I study combining nivolumab (anti-PD-1) with Ipilimumab 
(anti-CTLA4) in patients with advanced-stage melanoma, ORR were observed in 40% of 
patients treated with the combined regimen. At the maximum dose evaluated, 53% of treated 
patients had ORR, with over 80% of patients displaying some degree of reduction in tumor size 
(Wolchok et al., 2013). Interestingly, in a phase I study in which patients developed disease 
progression after receiving at least two doses of ipilimumab, such patients showed an overall 
response rate of 26% after subsequent treatment with pembrolizumab (Robert et al., 2014). These 
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findings suggest that combination therapies integrating multiple immune modulating agents may 
have the greatest potential to yield durable clinical benefits in cancer patients. 
Table 1. Current Therapies for Melanoma. 
Current therapy options for patients with melanoma remain ineffective in providing durable ORR in the absence 
of profound toxicity when applied as single modalities, making the design and implementation of combination 
therapies a  necessity [Adapted from: (Tentori et al., 2013)]. 
1.4 DNA DAMAGE RESPONSE 
All of the cells in our body are susceptible to DNA damage as a result of environmental insults, 
but are protected in their normal somatic integrity based on the intrinsic action of DNA repair 
mechanisms (Hoeijmakers, 2009). For Single Stand Breaks (SSB) in genomic DNA, cells 
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employ repair mechanisms like Mismatch Repair (MMR), Base Excision Repair (BER) and 
Nucleotide Excision Repair (NER), while for more toxic double strand DNA breaks (DSB), cells 
employ mechanisms including Non-Homologous End Joining (NHEJ) and Homologous 
Recombination (HR) (Hoeijmakers, 2001). In addition to DNA repair mechanisms, the DNA 
damage response also includes cell cycle checkpoint regulation, transcriptional program 
activation, and regulation of cell death mechanisms. Improper functioning of these DNA repair 
pathways results in genetic instability, that in the absence of cellular lethality, may result in the 
development of cancers, such as cutaneous melanoma (Hoeijmakers, 2009; Warmerdam & 
Kanaar, 2010). 
 
Figure 1. DNA Damage Response Mechanism. 
The exogenous damage caused by chemotherapy drugs that induces toxic double strand breaks (DSB) is an issue of 
concern that results in outcomes of incomplete repair in cancer cells, which results in development of resistance to 
the chemotherapy [Adapted from: (Kinsella, 2009)]. 
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1.4.1 Cell Cycle Checkpoint Regulation 
There are three cell cycle checkpoints – G1-S, S phase and G2-M; at which the cell attempts to 
recognize and remove/repair DNA damage. Checkpoints operationally allow for a period of cell 
cycle arrest during which efficient DNA damage repair may be carried out before the onset of 
cellular mitosis or replication, when the aberrant (irreparable) cells may be induced to undergo 
apoptosis (Zhou & Elledge, 2000). In the G1 phase of the cell cycle, the cell has only one copy 
of DNA present and the major DNA repair pathway for DSBs during this phase is NHEJ. 
Affected cells respond to DNA damage through the ATM(ATR)/CHEK2(CHEK1)-TP53/MDM2 
pathway ( Kastan & Bartek, 2004; Hinz et al., 2005; Warmerdam & Kanaar, 2010). The G1-S 
checkpoint is TP53-dependent and is regulated by ATM (Massagué, 2004). Cells entering S 
phase with unrepaired DNA lesions are arrested in the S phase which is regulated by ATR being 
recruited to single strand DNA by the RPA binding complex in order to activate CHEK1 which 
signals cell cycle arrest. This prevents premature mitosis, chromatin condensation and mitotic 
apoptosis (Pavey et al., 2013). The G2-M checkpoint stops cells with DNA damage from 
initiating mitosis. ATM/ATR and CHEK1/CHEK2 inhibit the activation of the mitosis-
promoting cyclin B/CDK1 kinase. The G2 checkpoint is partially maintained by BRCA1 and 
TP53 (Kastan & Bartek, 2004). Targeted interruption of these cell cycle checkpoints has been 
shown to sensitize cancer cells to the subsequent action of chemotherapeutic agents (Zhou & 
Bartek, 2004; Sankunny et al., 2014). 
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1.4.2 DNA Double Strand Break Repair 
The DSB is the most dangerous form of DNA damage and its repair is crucial for cell survival 
and genomic integrity. The two main mechanisms through which DSBs are repaired are: error-
prone NHEJ and an error-free mechanism based on HR between sister chromatids (Khanna & 
Jackson, 2001). 
 
Figure 2. DNA Double Strand Break Repair. 
Homologous recombination occurring via the error-free mechanism that predominantly occurs during the S or G2/M 
phase, and NHEJ, the error prone repair mechanism occurring at all phases of the cell cycle are the two major 
pathways used by cells to repair double strand breaks [Adapted from: (J. H. Hoeijmakers, 2001)]. 
1.4.2.1 Homologous Recombination (HR) 
HR operates predominantly in the late S or G2 phases of the cell cycle, since it is 
dependent on a sister chromatid for use as a template for resynthesizing regions of DSB damage 
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(Shiloh & Lehmann, 2004; Kelley et al., 2014). The MRN complex, comprised of MRE11, 
RAD50 and NBN acts as a “sensor” (Williams et al., 2007) that initiates the resection at the 5’ 
end on either side of DSB, creating a 3’-overhangs of single-strand DNA. ATM senses and may 
bind to the DSB, thereby activating/phosphorylating H2AX into γH2AX, which then attracts 
BRCA1 and NBN (Yuan et al., 2010; Sankunny et al., 2014). BRCA2 is recruited to the DSB by 
BRCA1, and facilitates the loading of RAD51 onto RPA-coated DNA overhangs with the help of 
RAD51 paralogs, which in turn, recruit RAD52 and RAD54. Accumulation of RPA leads to the 
activation of the ATR pathway (Shiloh, 2001). The tumor suppressor TP53, known to interact 
with BRCA1, RAD51, BLM and WRN, is also likely present within this DNA protein complex 
(Valerie & Povirk, 2003). The RAD51-coated single-stranded tail then searches for the 
homologous DNA sequence, and once identified, RAD51 mediates the strand invasion and 
successive ligation mediated by DNA ligase 1 to yield an intermediate structure known as a 
Holliday junction (Dexheimer, 2013; Kelley et al., 2014). There are then two possibilities to 
complete HR, either by non-crossing-over in which case the Holliday junctions disengage or by 
DNA strand pairing followed by gap filling (Hoeijmakers, 2001). 
1.4.2.2 Non-Homologous End Joining (NHEJ) 
NHEJ operates in all phases of the cell cycle in mammalian cells. The end-joining 
reaction in NHEJ simply links ends of a DSB together, without the need for a template, applying 
the end-binding XRCC5/XRCC6 complex to the exposed DNA termini of the DSB. After 
binding, the complex adopts a ring-shaped structure to encircle the DNA duplex. Once encircled, 
PRKDC is recruited to contact DNA termini (Walker et al.,  2001). After the appropriate 
processing of the DNA termini, ligation is carried out by DNA ligase 4 in conjunction with 
XRCC4-Ligase 4 (Hoeijmakers, 2001; Dexheimer, 2013). The cell cycle machinery, including 
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the DNA damage signaling protein kinases ATM and ATR, influences the DSB repair pathway 
choice (Hoeijmakers, 2001). 
1.4.3 DNA Repair Proteins as Targets for Immunotherapy 
Despite decades of research, and in spite of the recent advent and success of immune checkpoint 
blockade-based immunotherapeutic interventions, until recently, the most commonly applied 
treatment for melanoma (and indeed most forms of cancer) was chemotherapy (CT). In order to 
clinically reduce tumor size, CT causes “incorrectable” DNA lesions in treated tumor cells, most 
commonly DSBs (Fojo, 2001; Luqmani, 2005; Khan et al.,  2011). Moderately impacted tumor 
cells amplify DNA repair mechanism associated gene products in order to maintain viability and 
foster a state of CT-resistance (Kauffmann et al., 2008). In order to prevent such resistance and 
to increase melanoma sensitivity to CT, we chose to develop a novel immunotherapy approach 
targeting DNA repair proteins that have been highly-correlated with the progression of drug-
refractory disease after CT (Kauffmann et al., 2008). 
In particular, since CT may promote elevated expression of DSBs, critical DNA-RP in 
the HR and NHEJ pathways involved in DSB repair for focused immunologic evaluations were 
chosen; i.e., ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, PRKDC; XRCC6, XRCC5, MRN 
complex proteins (MRE11, NBN, RAD50) and RAD51 (Shiloh & Lehmann, 2004; Kauffmann 
et al., 2008; Stingl et al., 2012). 
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1.5 ROLE OF HSP90 IN CANCER 
Heat shock protein 90 (HSP90) is a highly-conserved molecular chaperone that is essential for 
the stability and proper folding of its client proteins. HSP90 helps these client proteins regain 
their native conformations and sustains their functionality under conditions of severe cellular 
stress. Many HSP90 client proteins play important roles in pro-cancer cellular processes, such as 
angiogenesis, metastasis, cell signaling, cell proliferation and cell survival. HSP90 aids cancer 
cells by protecting the activity of pro-tumor client proteins by refolding and stabilizing them in 
an environment that is not conducive to normal metabolic programming (i.e., the hypoxic 
microenvironment in tumors). This makes HSP90 an important target for the development of 
effective interventional cancer therapies. 
1.5.1 Heat Shock Proteins 
Heat shock proteins were first discovered more than 50 years ago when a puffing pattern was 
observed in the chromosomes of Drosophila under elevated temperature (Ritossa, 1962). By 
definition, heat shock proteins (HSPs) are proteins whose expression is elevated when the 
temperature increases above a physiologic norm. Expression of HSPs is also upregulated in 
response to other cellular stressors, including hypoxia, acidosis and physical pressure (De Maio, 
1999). HSPs serve as chaperones in helping other proteins recover from misfolding events that 
would typically inactivate those proteins and lead to their degradation via the macromolecular, 
multi-enzymatic proteasome complex (Blagosklonny, 2002). HSPs support a highly-conserved 
and primitive molecular salvage pathway that optimizes the likelihood of survival of cells under 
pathologically stressful conditions. 
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HSPs are highly abundant proteins (1-2% of the total proteome) in normal cells, with 
even higher levels (up to 5-6%) detected in tumor cells.  HSPs regulate the fate of thousands of 
intrinsic cellular proteins by facilitating the ATP-dependent refolding and reassembly of 
multiprotein complexes in the cytosol, endoplasmic reticulum and mitochondria, and are also 
involved in the intracellular transport and sorting of proteins (Buchner et al., 1999). HSPs consist 
of a large family of proteins that are individually classified based on their molecular weights; i.e., 
HSP10, HSP27, HSP40, HSP60, HSP70, HSP90, etc. (Li & Srivastava, 2004). 
1.5.2 Heat Shock Protein 90 (HSP90) 
Heat shock protein 90 is a highly-abundant, stress-inducible, homodimeric, ATP-dependent 
molecular chaperone. In normal cells, HSP90 exists as a free protein and its chaperone activity is 
modest. On the other hand, in cancer cells, HSP90 is frequently overexpressed and plays an 
important role in the maintenance of protein conformational integrity, stabilization of a number 
of oncogenic/survival proteins, supporting a cytoprotective response to the hypoxic and acidic 
tumor microenvironment (TME). In such a setting, HSP90 supports tumor progression and 
metastasis (Whitesell & Lindquist, 2005). In tumor cells, HSP90 forms the core of a super 
chaperone machine, consisting of HIP, HOP, HSP40 and HSP70, which have been shown to 
maintain the functional integrity of a growing list of client proteins, including signaling protein 
kinases, transcription factors, DNA-RP and other cytosolic or nuclear proteins (Taipale et al., 
2010). HSP90 client proteins are involved in each of the original six hallmarks of cancer cell 
physiology i.e., self-sufficiency in growth signal, insensitivity to growth-inhibitory mechanism, 
evasion of programmed cell death, limitless replicative potential, sustained angiogenesis and 
tissue invasion and metastasis ( Hanahan & Weinberg, 2000; Barrott & Haystead, 2013).  
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Most chemotherapeutic agents and small molecule inhibitors were selected for use based 
on the biased targeting of only one to two individual proteins or signaling mechanisms. Given 
the striking molecular heterogeneity of the aggregate tumor cell population in a given patient, 
such targeting predictably selects for tumor cell subpopulations that exhibit functional 
compensatory pathways that are refractory to the action of a given targeted treatment regimen. In 
contrast, the therapeutic targeting of HSP90 would theoretically lead to the coordinated 
disruption of multiple pathways supporting cancer survival and metastasis (Koga et al., 2009), 
reducing the odds for outgrowth of treatment-refractory disease. Additionally, since HSP90 is 
highly overexpressed in tumors, HSP90 targeting is more selective against cancer (versus normal 
cells)(Kamal et al., 2003). Therefore, inhibition of HSP90 has gained substantial traction as a 
novel cancer therapeutic strategy. 
1.5.3 HSP90 Structure & Function 
The HSP90 family consists of the cytosolic HSP90-α and HSP90-β, the ER HSP90B1 and the 
mitochondrial TRAP1 (Ciocca et al., 2013). In humans, HSP90-α and HSP90-β are closely-
related isoforms, that both become activated under cellular stress conditions(Csermely et al., 
1998; Goetz et al., 2003). HSP90 is a phosphorylated homodimer which contains two to three 
phosphate groups (Buchner et al., 1999). Each monomer in the homodimer consists of a highly 
conserved amino-terminal domain, a middle domain, which binds to HSP90-client proteins, and 
a carboxy-terminal domain that helps in dimerization. HSP90 has a highly-conserved ATP-
binding domain near the amino-terminal domain. This ATP-binding domain is comprised of an 
α- and β-sandwich motif (Taipale et al., 2010). After interacting with client proteins and co-
chaperones, binding and hydrolyzing of ATP takes place at the ATP-binding domain (Buchner et 
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al., 1999). The HSP90 dimer is a flexible structure due to the antiparallel association of the 
component C-terminal regions. The relative orientation of the domains allows HSP90 to adopt 
various conformations. A rise in temperature leads to the formation of a closed conformation by 
triggering an additional structural transformation that brings the N-terminal domains into close 
proximity (Barrott & Haystead, 2013). ATP binding to HSP90 leads to a “closed” conformation. 
Hydrolysis of ATP into ADP leads to a secondary state that remains structurally unresolved, with 
subsequent dissociation of ADP dissociation restoring HSP90 to its open conformation. The 
closed conformation in the ATP-bound state is the active form of HSP90, enabling this molecule 
to optimally function within the multi-component chaperone complex (Ciocca et al., 2013; 
Taipale et al., 2010). 
HSPs are regulated primarily at the transcriptional level by heat shock factor-1 (HSF1).  
HSF1 is constitutively expressed in cells (Ciocca et al., 2013). HSF1 is usually bound to HSP90 
and is inactive, however, under stressful conditions, HSF1 is released from HSP90 and becomes 
phosphorylated by protein kinases, which results in the formation of homotrimers that enter the 
nucleus and then bind to heat shock elements in the promoter region of the HSP90 gene and 
other HSP genes. HSP90 mRNA is transcribed after further phosphorylation and enters the 
cytosol where new HSP90 chaperone complexes are then assembled (Buchner et al., 1999; 
Richter & Buchner, 2001). 
Co-chaperones assist HSP90 throughout its conformational cycling, which is essential for 
optimal function, acting as substrate recognition proteins and even enhancing enzymatic activity. 
The tetratricopeptide repeat (TPR) domain containing proteins are the predominant class of co-
chaperones, which bind the MEEVD motif located in the C-terminus of HSP90. HSP70–HSP90 
organizing proteins (HOP) are co-chaperone proteins that interact with the C-terminus of HSP70. 
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Other co-chaperones that interact with HSP90 through alternative domains are activator of 
HSP90 ATPase homolog 1 (AHA1), which augments the function of HSP90 by stimulating its 
ATPase activity. Cell division cycle 37 (CDC37) is the co-chaperone that is most implicated in 
facilitating tumorigenesis, as it associates with mutant kinases that drive cancer progression 
(Stepanova et al., 1996). P23 is another co-chaperone that is responsible for the complexing of 
HSP90 and nuclear hormone receptors that has been found in a wide range of HSP90–client 
complexes. Unlike the activating co-chaperone AHA1, the co-chaperones CDC37, P23 and HOP 
inhibit ATPase activity. These co-chaperones therefore add an additional layer of regulation to 
this multifaceted master chaperone, underlining the complexity of the HSP90 chaperone cycle 
and its client protein salvaging functions (Buchner et al., 1999). 
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Figure 3. The HSP90 Superchaperone Salvages DNA-RP Clients. 
 HSP90 along with other molecular chaperones forms the mature complex capable of binding to client proteins (that 
have lost their structural and functional integrity in the stressful TME) and mediating their return to native 
conformation in support of cancer progression. Though this project focuses on the immune targeting of DNA-RP 
that represent HSP90 client proteins in cancer cells, the core paradigm for this work is applicable to all tumor-
associated client proteins of HSP90 [Adapted from: (Whitesell & Lindquist, 2005)]. 
1.5.4 HSP90 Client Proteins 
HSP90 has an ever-increasing number of known cellular client proteins. (For a comprehensive 
list of HSP90 client proteins, see http://www.picard.ch/downloads/Hsp90interactors.pdf). In the 
 20 
absence of HSP90-mediated stabilization, most unfolded client proteins undergo degradation. In 
tumor cells, mutated proteins that may represent oncogenes (such as BRAF(V600E)) may be 
unstable under stress conditions, but are retained/accumulated in cancer cells due to the 
corrective action by HSP90 (Blagosklonny et al., 1996).  HSP90 stabilizes oncoproteins such as 
BCR/ABL1, RAF1, ERBB2 and mutant forms of TP53; survival-signaling kinases such as 
AKT1 and PI3K; growth factor receptors such as VEGFA, PDGFRB and less stable proteins 
produced by DNA mutations (Fulda et al., 2010). A few of the protein kinases that play an 
important role in cancer progression are listed here. ERBB2 binds to HSP90 and to its 
endoplasmic reticulum homolog HSP90B1. It is a receptor tyrosine kinase that is overexpressed 
in many malignancies such as breast, prostate, gastric, and ovarian cancers. AKT1 is another 
protein kinase that controls cell proliferation and survival pathways and it therefore plays a role 
in cancer progression as it suppresses apoptosis. The inhibition of HSP90 using STA9090 results 
in the disassociation of CDC37 and CDK4, and a resultant reduction in the half-life of the CDK4 
protein. RAF1 protein kinase is associated with an HSP90 complex containing CDC37 and 
HSP90N. The BCR–ABL1 fusion protein P210 whose upregulation is associated with CML is 
also an HSP90 client protein. (Buchner et al., 1999) Steroid hormone receptors require HSP90 to 
maintain the appropriate receptor conformation for hormone binding. The most commonly 
mutated tumor suppressor product, TP53, requires HSP90 to achieve a stable conformation 
(Trepel et al., 2010). Furthermore, a transcription factor and HSP90 client protein important to 
oncogenesis is Hypoxia-inducible factor-1α (HIF1A), which plays a role in cancer progression 
by supporting tumor-associated glycolysis, glucose transport and angiogenesis (Zhang et al., 
2005). 
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The  pro-apoptotic kinase, ASK1 (apoptosis signal-regulating kinase 1) loses its activity 
as a results of a complex formation with HSP90-AKT1 (Neckers et al., 1999). HSP90 exerts anti-
apoptotic functions inside the mitochondria by interacting with TRAP1 (tumor necrosis factor 
receptor-associated protein 1), CYPD (cyclophilin D) and survivin. This also prevents AIF 
(apoptosis-inducing factor) mitochondrial-cytosolic translocation and inhibits the nucleolytic 
activities of both AIF and endonuclease G (Trepel et al., 2010). HSP90 also aids in cancer 
progression by promoting angiogenesis and metastasis through the chaperoning of specific client 
targets, including VEGFRs and PDGFRs, amongst others. Therefore, inhibition of HSP90 
function in the TME is expected to exert a range of biologic effects that are largely 
contraindicated for tumor cell survival/cancer progression (Sangster et al., 2004). 
HSP90 plays a crucial supportive role in tumorigenesis, as it is associated with a wide 
range of client proteins that are involved in tumor cell growth and metastasis. However, our 
understanding of HSP90 expression and function in various cancers continues to be incomplete. 
Much remains to be learned with regards to HSP90 activity in tumor cellular processes such as 
energy metabolism, protein trafficking, epigenetics and DNA quality-control. Many client 
proteins that play a role in DNA-damage response have been identified (Schmidt-Ullrich et al., 
2003; Dote et al., 2006; Jewell et al., 2010; Stecklein et al., 2012; Guida et al., 2012; Ha et al., 
2011; Ko et al., 2012; Che et al., 2013; Acquaviva et al., 2014; Pennisi et al., 2015) and are listed 
in Table 2. To aid in future studies of HSP90 functional impact in the cancer setting and to serve 
as possible therapeutics, many HSP90 inhibitors (HSP90i) have been developed over the past 
decades. 
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HSP90 has several client proteins that play a role in the DNA damage response, with many of these proteins playing 
roles in more than one particular pathway. Overexpression of these proteins in cancer cells has been correlated with 
chemo resistance. However, the impact of HSP90i on the tumor cell-expressed components of the HR and NHEJ 
pathways remain unknown [Adapted from: (Dietlein et al., 2014; Pennisi et al., 2015)]. 
1.5.5 HSP90i 
Since HSP90 is an ATP-dependent chaperone machine, drugs that interact with ATP-binding 
sites of kinases have been tested for their ability to inactivate HSP90 chaperone activity. 
Galdanamycin (GA), the first identified inhibitor of HSP90 chaperone activity, was originally 
thought to function solely as a kinase inhibitor, but then later found to be a HSP90 inhibitor that 
Table 2. HSP90 DNA Repair Client Proteins. 
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could have clinical benefit. (Neckers & Ivy, 2003). Many GA-derived HSP90 inhibitors 
(HSP90i) were developed that were classified as first generation inhibitors. However, the first 
generation of inhibitors displayed substantial toxicity in cancer patients. The second-generation 
of inhibitors developed still required intravenous administrations on a weekly basis, but had 
greater bioavailability and exhibited less hepatic toxicity. Second-generation inhibitors are taken 
orally and have been demonstrated to be more stable, less toxic and exerted greater anticancer 
properties. There are currently 17 different HSP90 inhibitors that have been tested in clinical 
trials involving over 1000 cancer patients (Proia & Kaufmann, 2015; Trepel et al., 2010).  
The impact of HSP90i on the tumor cell-expressed components of the HR and NHEJ 
pathways still remains unknown. However, previous reports have identified several DDR 
proteins including ATR, CHEK1, BRCA2, PRKDC and the MRN complex as client proteins of 
HSP90 (Schmidt-Ullrich et al., 2003; Dote et al., 2006; Jewell et al., 2010; Ha et al., 2011; 
Stecklein et al., 2012; Guida et al., 2012; Ko et al., 2012; Che et al., 2013; Acquaviva et al., 
2014; Pennisi et al., 2015). Notably, in all of these studies, investigators focused on just one, or 
only a small subset of protein targets.  
 
Figure 4. HSP90 Inhibitor Developmental Timeline. 
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GA was the first drug that was identified as an HSP90 inhibitor. Many GA-derived HSP90 inhibitors classified as 1st 
generation HSP90i showed modest potency in phase I clinical trials but had significant cardiac and liver toxicities 
associated with them. The 2nd generation inhibitors addressed the toxicity issues and also exhibited higher potency. 
STA9090, in particular had shown promising results in phase I/II clinical trials and is currently in a phase III clinical 
trial for the treatment of patients with NSCLC. 
1.5.5.1 STA9090 
STA9090 (aka, Ganetespib) when compared to the 1st generation drug 17-AAG, exhibits 
higher competitive binding to the ATP binding site at the N-terminal domain of HSP90 (Soga et 
al., 2013). This shifts HSP90 from a refolding chaperone complex to a form that promotes client 
proteins polyubiquitination and subsequent degradation by the 26S proteasome (Ha et al., 
2011). STA9090 has shown promising results in both preclinical and phase I/II clinical trials in 
the setting of melanoma, metastatic breast cancer and NSCLC. STA9090 appears to work better 
when applied in combination rather than as a single modality drug, as may be the case for other 
previously investigated HSP90i (Proia et al., 2012; Socinski et al., 2013; He et al., 2014; Jhaveri 
et al., 2014).  
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        Figure 5. STA9090 Degrades Client Proteins through a Proteasome-Dependent Processing Pathway.  
STA9090 prevents the HSP90 mature complex from binding to the client DNA-RPs by binding to the ATP site 
instead. Unchaperoned DNA-RPs client proteins then get degraded through a proteasome-dependent pathway, 
leading to increased sensitivity of tumor cells to the chemotherapeutic agents. 
1.5.6 Combinational Anti-Tumor Therapy Integrating HSP90i 
When applied as a single modality, HSP90i have yielded only modest anti-tumor efficacy and 
discernable toxicity. However, combination therapies integrating HSP90i in concert with 
chemotherapy and/or radiotherapy (CRT) have yielded encouraging results, with HSP90i pre-
treatment appearing to sensitize tumor cells to subsequent CRT (to be discussed in more detail in 
Chapter 3). No studies have focused on the ability of HSP90i to alter immune reactivity against 
HSP90 client DNA-RPs, which speaks to the novelty of the current project. 
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1.6 CANCER IMMUNOTHERAPY 
1.6.1 Cancer Immunity 
The immune system has the ability to distinguish self from non-self cells and to destroy such 
invaders. Tumor immunology is somewhat more complicated, in that the host immune system 
must be able to differentiate tumor cells from normal cells based on antigens that are uniquely 
(i.e., mutated) or differentially (based on higher levels of protein) expressed by the diseased cells 
(Melvold & Sticca, 2007; Finn, 2008). In particular, host T cells can only be triggered to react to 
target cells if the level of cognate peptide presented in the context of MHC class I or class II 
molecules exceeds a threshold established as a consequence of “negative” selection during the 
neonatal self-tolerance programming of the host’s T cell repertoire (Grossman and Paul, 2015). 
An improved understanding of the tumor antigens recognized by the T cells and the specific 
peptide sequences presented in MHC molecular complexes has helped to improve the efficacy 
and monitoring of immunotherapies over the past 25 years (Harris et al., 2013).  
In 1991, van der Bruggen and colleagues were the first to use expression cloning 
techniques to identify a melanoma antigen recognized by CD8+ T cells, which they termed 
MAGEA1 (Bruggen et al., 1991). Since then, over 100 melanoma-associated tumor antigens 
recognized by T cells have been defined (Yang, 2011). The tumor associated antigens described 
for melanoma can be mainly divided into four major classes. 1) Differentiation antigens, such as 
the melanocyte-specific proteins like MLANA, MSH1, Tyrosinase and tyrosinase-related 
proteins; 2) Embryonically-expressed proteins, also known as cancer-testis antigens like the 
MAGE family of proteins and CTAG1B; 3) Tumor-specific mutated proteins that produce 
immunogenic epitopes that are naturally-processed and -presented, as perhaps best exemplified 
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by CTNNB1 and CDK4 (Kawakami et al., 1996); and  4) Tumor overexpressed proteins that 
support the malignant phenotype or transformation process. These latter proteins can have 
important functions in normal tissues, as in the case of wild-type TP53, which is frequently 
overexpressed in cancer cells due to pairing with a mutated TP53 allele (Cohen et al., 2005; 
Yang, 2011). The DNA-RP overexpressed in melanomas that are responsive to upregulation after 
chemotherapy would fall into category 4 above. This project represents a first attempt to 
investigate tumor overexpressed proteins involved in DSB pathway as cancer-specific antigens 
that can be targeted by T cells. 
1.6.2 Cancer Immunotherapy 
The concept of cancer immunotherapy is to use a patient’s immune system to recognize, attack 
and reject their own malignant cells (Rosenberg et al., 2004). Several different approaches have 
been used to achieve this goal. By administering cancer vaccines, a patient’s own immune 
system is educated to expand T cells that are capable of recognizing and killing their own tumor 
cells. Similarly, therapeutic antibodies (reactive against tumor cell surface antigens) or certain 
cytokines may be applied to facilitate immune cell-mediated destruction of tumor cells. 
Adjuvants (including cytokines, toll-receptor ligands, and even purified or recombinant HSP90) 
can be used to activate and mature endogenous patient Dendritic Cells (DC), Natural Killer Cells 
(NK cells), and Cytotoxic T Lymphocytes (CTLs) to mediate heightened anti-tumor immunity 
(Waldmann, 2003; Rosenberg et al., 2004). Amongst the myriad of  cancer immunotherapy 
approaches developed over the past 50 years, adoptive cell therapy (ACT) and monoclonal 
antibody therapies targeting immune checkpoint molecules such as CTLA-4 and PD-1/PD-L1 
have emerged as preferred treatment modalities (Rosenberg et al., 2008). 
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1.7 ADOPTIVE CELL THERAPY 
Adoptive cell therapy is personalized cancer therapy that has emerged as an effective treatment 
for metastatic melanoma patients. ACT involves the generation of anti-tumor T cells from the 
blood or tumor of a cancer patient, with subsequent expansion of T cells ex vivo with subsequent 
reinfusion of these cytotoxic immune effector cells back into the same patient (Johnson et al., 
2006; Rosenberg et al., 2008). 
1.7.1 Tumor-Infiltrating Lymphocyte (TIL) Therapy 
The typical procedure for TIL therapy involves the process of TIL expansion where resected 
tumor is cut into small fragments that are cultured in the presence of high-doses of IL2, with the 
tissue-resident TIL expanding for several weeks (using a so-called Rapid Expansion Protocol 
(REP) using anti-CD3 in the presence of antigen-presenting cells along with rIL2) before being 
reintroduced into the cancer patient by i.v. infusion (Wu et al., 2012). Studies have shown that 
TILs present in tumor tissues play an important role in both cancer progression and cancer 
treatment (Liao et al., 2013). The identification of the REP, enabling generation of large numbers 
(i.e., 109-1012) of T cells was key to the development of adoptive cellular therapy; (Muul et al., 
1987; Rosenberg et al., 2008). Clinical trials for metastatic melanoma have shown that the 
combination of TIL ACT with systemic administration of rIL2 results in tumor regression in 50 
to 70% of treated patients (Dudley et al., 2008). There have been clinical trials performed using 
“young TIL” without implementation of a REP. This technique results in more TIL and an 
accelerated schedule to treat most enrolled patients. The results of this protocol suggest that 
lympho-depleting chemotherapy followed by young TIL ACT may lead to tumor regression in 
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50% of advanced-stage melanoma patients with manageable toxicities (Besser et al., 2010). In an 
alternate study using young TIL and NMA, 58% of advanced-stage melanoma patients exhibited 
objective clinical responses (OCR), while treatment with young TIL and 6 Gy irradiation yielded 
48% OCR, with 4% complete responses (Dudley et al., 2010). 
1.7.2 Genetically Engineered T Cell Therapy 
Since it is not possible to obtain tumor-reactive TILs from all cancer patients for the purpose of 
delivering ACT, there has evolved the need to achieve this goal by genetically-modify large 
numbers of autologous T cells to exhibit anti-tumor specificity (Zhou & Zhou, 2014). In this 
process, bulk patient T cells are infected with a recombinant retroviral vector encoding either a 
tumor-specific T-cell receptor (TCR) or a chimeric antigen receptor (CAR) based on an antibody 
reactive against a tumor cell surface antigen (Rosenberg et al., 2008;  Zhou & Zhou, 2014). 
CARs differ from TCRs as they target native cell surface antigens that do not require peptide 
processing or HLA-presentation, whereas, TCRs engage specific HLA-peptide complexes that 
need to be matched with a cancer patient’s MHC haplotype (Sadelain et al., 2013). TCR-based 
ACT therapies targeting CTAG1B have led to tumor regression in patients with metastatic 
synovial cell sarcoma and melanoma, with 18% of patients with melanoma exhibiting complete 
tumor regression that persisted for over 1 year (Robbins et al., 2011). While there are several 
studies reporting clinical efficacy using CAR-T cell therapy targeting CD19 in acute 
lymphoblastic leukemia, chronic lymphoblastic leukemia, multiple myeloma and lymphoma (Dai 
et al.,  2016), these are mostly limited to the treatment of hematological malignancies. In the end 
though, the anti-tumor impact of CAR-T cell-based therapy in solid tumors may be limited due 
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to the more suppressive TME of solid cancers and due to the well-known antigenic heterogeneity 
of the aggregate target cell population (Khalil et al., 2016). 
1.8 MHC CLASS 1 PRESENTATION PATHWAY 
Over the last 25 years, the necessity of MHC class I expression for the presentation of antigens to 
cytotoxic T lymphocytes has been made clear. The MHC class I antigen presentation pathway 
involves the processing of endogenous self or viral proteins for presentation of their peptides in 
the context of MHC class I molecules that are expressed on the surface of all somatic, nucleated 
cells in the body (Ramirez & Sigal, 2004). MHC class I molecules present peptides that are 
approximately 8-12 amino acids in length to specific subpopulations of CD8+ T cells. This 
allows CD8+ T cells circulating in the blood system to police peripheral tissues in search of 
aberrant infected or diseased cells, and to eradicate them in defense of the health of the host 
organism. Indeed, MHC class I-restricted cytotoxic T lymphocytes (CTL) responses are critical 
for effective anti-tumor immunity (Overwijk et al., 2003). MHC class I-restricted peptide 
presentation occurs via two distinct pathways, the direct- and cross-presentation pathways. Due 
to defects in MHC molecule expression or antigen processing machinery, and/or a skewed 
balance towards co-inhibitory over co-stimulatory molecule expression, tumor cells are generally 
considered to be poor antigen presenting cells (APC) to T cells (Storkus et al., 2007). Rather, T 
cell responses are elicited efficiently by professional APC, such as dendritic cells, through 
antigen cross-presentation to initiate a protective CD8+ T cell (including CTL) responses against 
tumor cells.   
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Figure 6. MHC Class I Pathway. 
Proteins are processed by the proteasome in the cytosol and produce peptides and are translocated into the 
endoplasmic reticulum by the TAP1/TAP2 complex in an ATP-dependent manner. MHC class I-restricted peptide 
presentation occurs via two distinct pathways, the direct- and cross-presentation pathways before the peptides are 
transported to the surface for presentation [Adapted from: (Villadangos & Schnorrer, 2007)]. 
In the direct presentation pathway, intrinsic unfolded tumor-associated proteins such as 
ERBB2 and mutant BRAF, among others, may be retro-translocated into the cytoplasm via a 
SEC61A1-dependent mechanism, where they may be degraded by the multi-catalytic proteasome 
complex. Peptides, 8-10 amino acids in length, may be translocated from the cytosol into the ER 
by the transporter of antigenic peptide (TAP)-1/-2 molecules for binding in nascent MHC class I 
complexes (Heath et al., 2004). Longer peptides that are sufficiently stable in their interactions 
with MHC class I molecules enter the ER and may also be trimmed by an ER-resident 
aminopeptidases (ERAP1) (Elliott, 2006).  
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In the cross-presentation pathway, exogenous antigens are internalized by APC vi 
phagocytosis, endocytosis, pinocytosis or micropinocytosis. This cross-presentation pathway 
may compete with the MHC class II presentation pathway for exogenous antigens. Cross-
presented antigens are transferred to the cytosol through a mechanism similar to ERAD 
(degradation of newly-synthesized and misfolded proteins), followed by proteasome-mediated 
degradation and transport into the ER by TAP, before final loading into newly-formed MHC-I 
complexES  (Ramirez & Sigal, 2004; Villadangos & Schnorrer, 2007). 
HSPs also contribute to the function and orchestration of the antigen-processing and 
MHC-presentation machinery of tumor cells which directly impact the ability of these aberrant 
cell populations to be recognized and regulated by protective T effector cells (Binder & 
Srivastava, 2005; Zhou & Binder, 2014). Furthermore, HSP90 plays a critical role in antigen 
cross-presentation, in which DCs bind to extracellular antigens, internalize them in endosomes, 
and then translocate them from endosomes into the cytosol for degradation by the proteasome 
(Imai et al., 2011). 
Notably, HSP90i have been reported to enhance tumor cell MHC molecule expression 
and/or tumor antigen-derived peptide presentation by MHC I/II molecules on the surface of 
tumor cells, thereby facilitating the ability of moderate avidity T cells to recognize and react 
against treated tumor cells vs. untreated tumor cells or normal cells (Haggerty et al., 2014; 
Kawabe et al., 2009; Lin et al., 2007). Such conditional HSP90i-dependent alterations in the 
MHC-presented “peptidome” allow at least certain species to exceed the operational tolerance 
threshold of the host’s T cell repertoire, allowing for the activation and mobilization of a 
previously silent T effector cell cohort with potential to mediate anti-tumor activity. Modulations 
in tumor immunogenicity induced by interventional drugs such as HSP90i becomes even more 
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important clinically given pervasive reports for MHC and antigen-processing/presentation 
abnormalities in heterogeneous cancer cell populations in vivo that correlate with low levels of 
MHC-peptide complexes on the tumor cell surface, and with disease progression and poor 
patient survival (Lampen & Hall, 2011; Leone et al., 2013; Seliger, 2014). 
Once on the cell surface, these MHC class I/peptide complexes may be surveyed by host 
CD8+ T cells, some of which may mediate tumoricidal function (i.e., Type-1 CD8+ T cells). For 
the purposes of this study, we propose that HSP90i (such as STA9090) can transiently bias MHC 
class I occupancy towards peptides derived from HSP90 client proteins involved in DNA repair 
in order to facilitate recognition by protective, antigen-specific CD8+ T cells.  
 
Figure 7. Rationale behind Combining HSP90i with Adoptive Cell Therapy. 
 In addition, previous work by our group suggests that HSP90i can coordinately reduce levels of immunosuppressive 
cell populations in the TME, including MDSC and Treg. The ability of HSP90i to promote enhanced antitumor 
activity from T effector cells (via ACT), while removing regulatory immunity in the TME supports the expectation 
for the superior antitumor efficacy of combined HSP90i + ACT approaches in the cancer-bearing host.  
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1.9 PUBLIC HEALTH SIGNIFICANCE 
Cutaneous melanoma is the result of malignant transformation of melanocytes that characterizes 
1–2% of the total cell population found in the human epidermis. Since the mid-1960s melanoma 
represented considerable public health burden due to its substantial rise in incidence of about 3–
8% per year in Caucasian populations worldwide (Thompson et al., 2005). Patients diagnosed 
with metastatic melanoma to distant sites have a median survival of only 4–6 months (Guida et 
al., 2012). Considering how sun and UV exposure are considered as critical environmental risk 
factor for melanoma, the effectiveness of DNA repair of UV-induced DNA lesions is directly 
responsible for cancer prevention and a list of DNA repair genes that are involved in developing 
distant metastasis or survival has been developed (Kauffmann et al., 2008). In this study, we 
focused on immune targeting of DNA-RP associated with resistance to CT and how HSP90i 
might beneficially modulate such recognition. In particular, while HSP90i are expected to 
decrease melanoma resistance to subsequent CT, we proposed that treated tumor cells will also 
become more susceptible to immune-mediated killing by DNA-RP-specific CD8+ T cells, and 
that combination therapy integrating HSP90i and specific vaccination against HSP90 client 
DNA-RP will provide a more effective and durable treatment option for patients (in our case 
mice) with melanoma. In order to facilitate translation of our findings to the clinic, we used 
HSP90i that are currently in phase III clinical trials and took precautions to make sure that the 
lowest effective dosage of drugs was applied to avoid toxicity and to increase the treatment’s 
safety index. Innovation. No studies have thus far focused on the ability of HSP90i to 
conditionally increase the degradation and subsequent presentation of DNA-RP-derived peptides 
in MHC class I complexes to the immune system in vivo. We hypothesized that HSP90i will 
upregulate the stoichiometry of a pool of HSP90 client protein-derived peptides presented in the 
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global “repertoire” of MHC class I/peptide complexes presented on the tumor cell surface, 
allowing for improved tumoricidal action of specific CD8+ T effector cells. If validated, these 
studies will serve as a foundation for the design and clinical implementation of novel 
combination immunotherapies for patients with melanoma. 
 
Figure 8. Thesis Rationale. 
Chemotherapy causes many single strand and double strand lesions in cancer cells that induce corollary DNA repair 
mechanisms. In this process DNA-RPs become overexpressed in cancer cells, in association with resistance to 
genotoxic chemotherapies.  Many DNA-RPs that play key roles in the DSB pathway are clients of HSP90, with 
HSP90 serving to maintain the structural and functional stability of these DNA-RP, leading to enhance tumor cell 
survival and the progression of chemotherapy-resistant disease. Our hypothesis posits that if we inhibit HSP90 using 
inhibitors like STA9090, these will destabilize the pool of tumor-sustaining DNA-RPs by forcing them to undergo 
proteasomal degradation. This provides a conditional pool of peptide substrates for loading into MHC class I 
complexes that may be recognized for several days by therapeutic anti-DNA-RP specific CD8+ T cells that may be 
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elicited via vaccination or delivered by ACT. By also conditioning the TME (by removing regulatory cells), HSP90i 
may allow therapeutic T cells to mediate their tumoricidal activity in an unopposed manner, resulting in improved 
treatment benefits.  
The major hypothesis to be tested in this project is that HSP90i can conditionally sensitize 
melanoma cells to the tumoricidal action of CT as well as CD8+ T cells reactive against 
overexpressed DNA-RP that constitute HSP90 client proteins. The Specific Aims of my thesis 
project are: 
 Specific Aim 1: To characterize the expression of DNA-RP client proteins by melanoma cells 
and determine the comparative anti-melanoma efficacy of combined CT +/- HSP90i therapy in 
vitro and in vivo (Chapter 3). 
Specific Aim 2: To explore the anti-melanoma efficacy of combined therapy using HSP90i and 
specific vaccines or adoptive-transfer of CD8+ T cells reactive against DNA-RP in vivo (Chapter 
4). 
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2.0  MATERIALS AND METHODS 
2.1 MICE 
Six- to ten-week-old female C57BL/6 (H-2b mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME) and maintained in a pathogen-free animal facility in the South Biomedical 
Sciences Tower at the University of Pittsburgh. All animal experiments were performed in 
accordance with a University of Pittsburgh Institutional Animal Care and Use Committee 
(IACUC)-approved protocol. 
2.2 TUMOR CELL LINES  
The B16 murine melanoma (H-2b) cell line was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). B16 is an HLA-A2neg, mMART-1+, mgp100+ melanoma cell 
line (syngenic to the H-2b background of C57BL/6 mice) The murine BRAFV600EPTEN-/- 
melanoma cell line BP (Cooper et al., 2014) was kindly provided by Dr. Jennifer Wargo 
(University of Texas M.D. Anderson Cancer Center, Houston, TX) and then selected for 
resistance to the BRAF inhibitor, Dabrafenib (20 µM) for 1 month in vitro, yielding the BP20 
cell line, which established and progressed more uniformly than the parental tumor cell line after 
s.c. implantation in C57BL/6 mice (Fecek et al., unpublished results). The human metastatic 
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melanoma cell lines, Mel526 (HLA-A2+) and Mel624 HLA-A2+) were the kind gifts of Dr. 
Steven Rosenberg (National Institutes of Health, Bethesda, MD). The EL4 (H-2b, ATCC) 
thymoma was used as a negative control target for CD8+ T cell recognition assays. All tumor cell 
lines except EL4 were cultured in complete medium (CM1; RPMI 1640 media supplemented 
with 100 units/mL penicillin, 100 μg/mL streptomycin, 10 mmol/L L-glutamine, and 10% heat-
inactivated fetal bovine serum; all purchased from Life Technologies, Grand Island, NY) in a 
humidified incubator at 37°C and 5% CO2. EL4 cells were cultured in complete medium (CM2; 
DMEM medium supplemented with 100 μg/mL streptomycin, 10 mmol/L L-glutamine, and 10% 
heat-inactivated fetal bovine serum; all purchased from Life Technologies, Grand Island, NY) 
All cell lines were screened as negative for adventitious pathogens and for authentication by 
IDEXX BioResearch (Westbrook, ME). 
2.3 WESTERN BLOTTING 
Melanoma cell lines were grown to 80–90% confluence and then incubated with Temozolomide 
(50 µM, Selleck Chemicals, Houston, TX) for 12h, in the absence or presence of the HSP90i 
STA9090 (50 µM; Synta Pharmaceuticals, Lexington, MA) and/or the proteasome inhibitor 
MG132 (10 µM; Sigma-Aldrich, St. Louis, MO) for an additional 12h. In the test comparing 
DNA-RP expression with different chemo-toxic drugs +/- HSP90i, Dabrafenib (20 µM), 
Dasatinib (100 µM), Doxorubicin (0.1 µM), B16 murine melanoma cells were treated overnight 
for 12h. Alternatively, animals were euthanized, and progressively growing tumors from control 
or TMZ +/- HSP90i treated tumor-bearing mice were isolated by surgical dissection. Harvested 
cells/tissues were then incubated with lysis buffer. Lysates were cleared by centrifugation at 
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13,500 x g for 10 min, and proteins in the lysate resolved by SDS-PAGE prior to electro-transfer 
onto polyvinylidene difluoride (PVDF) membranes, as previously described (Kawabe et al., 
2009). After blocking with 5% non-fat dry milk (NFDM) for 30 min, the membrane was 
incubated overnight with primary antibodies at 4oC for specific anti-DNA repair proteins, HSP90 
or β-actin. The primary antibodies used against DNA-RP were: Rabbit anti-ATR (1:15,000 
dilution), mouse anti-PRKDC (2 µg/ml), mouse anti-MRE11 (3µg/ml), rabbit anti-NBN 
(1:10,000 dilution), rabbit anti-RAD50 (1:1000 dilution), mouse anti-RAD51 (1 µg/ml), rabbit 
anti-HSP90 (2 µg/ml), or rabbit β-actin pAb antibodies (1:10,000 dilution; all Abs from Abcam, 
Cambridge, UK). Blots were imaged for 1- 5 minutes on Kodak X-Omat Blue XB-1 film 
(Eastman Kodak, Rochester, NY) after incubation with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit Ig or goat anti-mouse Ig antibodies (1:10,000 dilution for both; Santa 
Cruz Biotechnology) and the Western Lighting chemiluminescence detection kit (Perkin-Elmer, 
Waltham, MA).  
2.3.1 Densitometry analysis of protein bands  
Densitometry analysis was performed using a GDS 8000 bioimaging system and LabWorks4.6 
software (UVP, LLC, Upland, CA). Relative optical densities were calculated for specific protein 
of interest and loading control (β-actin) for all lanes using one of the lanes as a reference. 
Adjusted densities were then calculated for each sample by normalizing the relative density of 
the protein of interest to the loading control for the same. 
                                    
         Adjusted density = Density of the protein of interest 
                                          Density of the loading control 
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2.4 QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION (QPCR).  
Total RNA was extracted from either treated melanoma cell lines or total resected tumors from 
treated mice using the RNeasy Plus Mini Kit (Qiagen) including the gDNA Eliminator column. 
The Nanodrop ND-1000 (CellBio SpA, Milan, Italy) was used to check the quality and quantity 
of RNA. Total RNA (1µg) was reversed transcribed into cDNA using the High Capacity RNA to 
cDNA kit (Life Technologies) and the cDNA added to Fast SYBR® Green Master Mix (Life 
Technologies) and used for quantitative PCR. Reactions were performed on a StepOnePlusTM 
Real-Time PCR thermocycler (Applied Biosystems) using the recommended cycling conditions. 
All mRNA expression levels were normalized to the expression of the cellular housekeeping 
gene product Hprt. Primer sequences were selected using Primer-BLAST Genbank and are listed 
in Table 3. 
 
Table 3. Real-time (qPCR) Primers used to Amplify Murine DNA-RP Transcripts in this study. 
DNA-RP Primer (forward 5’-3’) Primer  (reverse) Amplicon size (bp) 
Atr TTGGAAGGGCAGCAAAAGGA CTCCAGAGACGGATGCAGAC 90 
Prkdc GACAAGTGCAGAAATGGAAGCA CAGCCTGGCTTCAGAAGAGT 88 
Mre11 GCCCCACAGATCCACTTGAC TTCCTCTAACTGCATCTTTCTCCA 96 
Nbn CGGCTCCAGGAGAACCATAC ATGCCACAGTTTTTCCTCCCA 70 
Rad50 GCGTGCGAAGTTTTGGGATA AATGATGGTCGTCTTCCCCG 107 
Rad51 GCTGATGAGTTTGGTGTCGC TTGGGATCTGCAGCGAACAT 86 
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2.5 ADOPTIVE CELL THERAPY 
2.5.1 Selection of MHC class I-presented DNA-RP peptide epitopes 
Specific DNA-RP peptides used in this study are listed in Table 4. These peptides were selected 
based on ranked scores generated in a web-based algorithm. Used peptide binding algorithms 
(SYFPEITHI, BIMAS and IEDAR) predictive of the ability of peptides to be produced from 
parental proteins by proteasomal processing combined with their ability to bind (and be 
presented by) either H-2Db or H-2Kb class I molecules (http://www.iedb.org/). All 30 peptides 
were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry by the University of 
Pittsburgh Cancer Institute Peptide Synthesis Facility (a Shared Resource). Peptides were >96% 
pure based on high performance liquid chromatography profile and mass spectrometric analysis 
performed by the University of Pittsburgh Cancer Institute Protein Sequencing Facility (a Shared 
Resource). 
Table 4. Mouse DNA-RP  Peptides Sequenced. 
DNA-RP Peptide Sequence Length 
 (H-2 
restrict) 
Prediction 
Score 
ATM SSFPFMLL 
SSYKFLPL 
FMLLNYTSI 
8 (Kb) 
8 (Kb) 
9 (Db) 
0.10 
0.10 
0.10 
 ATR LSFAYGLL 
MNVQNVEFI 
8 (Kb) 
9 (Db) 
0.10 
0.20 
BRCA1 KSCMNQVTV 
AQRFFHQL 
9 (Db) 
8 (Db) 
0.40 
1.00 
BRCA2 RALNNYRQM 
IDIVNTLPL 
9 (Db) 
9 (Db) 
0.10 
0.20 
 CHEK1 HMLVNSQLL 
SNLDFSPV 
MTRFFTKL 
9 (Db) 
8 (Kb) 
8 (Kb) 
0.10 
0.25 
0.30 
 CHEK2 KLYFYQML 
GTFVNTELI 
8 (Kb) 
9(Db) 
0.25 
0.40 
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Table 4 (continued) 
PRKDC LFYKFVPL 
SALINLVEF 
8 (Kb) 
9 (Db) 
0.10 
0.10 
ERCC1 LSLRYHNL 8 (Kb) 0.10 
XRCC6 SSTLFSAL 
QHFRNLEAL 
8 (Kb) 
9 (Db) 
0.10 
0.10 
MRE11 NSWFNLFVI 
VNYQDGNL 
9 (Db) 
8 (Kb) 
0.10 
0.20 
 NBN SAPVNMTTY 
VGITNTQLI 
9 (Db) 
9 (Db) 
0.10 
0.20 
RAD50 RQIKNFHEL 
RNYNYRVV 
9 (Db) 
8 (Kb) 
0.10 
0.20 
RAD51 KELINIKGI 
VESRYALL 
9 (Db) 
8 (Kb) 
0.70 
0.75 
XRCC1 RQYMFSSL 
NPVENFRFL 
8 (Kb) 
9 (Db) 
0.10 
0.20 
2.5.2 In vitro generation of bone marrow–derived dendritic cells 
Dendritic cells were generated from bone marrow precursors isolated from the tibias/femurs of 
C57BL/6 mice. Bone marrow cells were cultured in CM1 supplemented with 10% heat-
inactivated fetal bovine serum, 1,000 units/mL recombinant murine granulocyte/macrophage 
colony-stimulating factor (rmGM-CSF) and 1,000 units/mL rmIL-4 (Peprotech) at 37°C in a 
humidified, 5% CO2 incubator for up to 5-6 days. 
2.5.3 Adenoviral infection of dendritic cells 
Five million (day 5 cultured) dendritic cells were infected at a multiplicity of infection of 50 with 
recombinant adenoviruses encoding mouse IL-12p70 (Ad.IL-12) (i.e., DC.IL12; known to 
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promote T helper-independent activation of Type-1 CD8+ T (Tc1) cells) as previously described 
(Zhao et al., 2011). After 48 h, infected dendritic cells (i.e., DC.IL12) were harvested. They were 
pulsed for 4h at 37oC with pools of peptides derived from DNA-RP as indicated (with each 
individual peptide present at a concentration of 1 µM). Viral vectors. The Ad.mIL-12p70 
recombinant adenoviral vectors were produced and provided by the University of Pittsburgh 
Cancer Institute Vector Core Facility. 
2.5.4 Generation of DNA-RP-specific CD8+ T cells for adoptive transfer therapy 
To generate Ag-specific CD8+ T cells for adoptive cell transfer experiments, naïve C57BL/6 
(tumor-free) mice were vaccinated s.c. (right flank) on days 0, 7 and 14 with a vaccine consisting 
of syngenic bone marrow-derived DC.IL12 that were pulsed for 4h at 37oC with pools of 
peptides derived from DNA-RP as indicated.  One week after the 3rd vaccination (i.e., day 21), 
the animals were euthanized, spleens harvested and CD8+ splenic T cells (MACSTM-selected; 
Miltenyi Biotec, Auburn, CA). T cell specificity was determined in IFN-γ ELISA against 
melanoma vs. control EL4 vs. DNA-RP peptide-pulsed EL4 target cells. For adoptive cell 
therapy experiments, 1-5 million CD8+ splenic T cells were fluorescently labeled using the cell 
tracker Deep Red Dye (5 μM, Thermofisher) for 30 min at 37oC, just prior to washing and i.v. 
injection (in PBS) into melanoma-bearing mice.   
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Figure 9. Adoptive Cell Therapy in Melanoma-bearing Mice. 
Naïve C5BL/6 mice were vaccinated thrice with DC.Ad.IL12 pulsed with DNA-RPs, 1 week after the 3rd 
vaccination CD8+ splenic T cells were obtained and fluorescently labeled using the cell tracker deep red dye before 
intravenous (i.v.) injection into the tail vein of B16 melanoma-bearing mice. 
2.6 TUMOR ESTABLISHMENT AND THERAPY MODELS 
Tumors were established by injection of 1 x 105 B16 melanoma cells sub-cutaneously (s.c.) into 
the right flank of syngeneic C57BL/6 mice. For therapy models, tumors were allowed to 
establish through day 6, at which time animals were randomized into cohorts of 5 mice/group, 
with each cohort exhibiting a mean tumor size of approximately 35 mm2. For standard 
chemotherapy experiments, mice were treated with intraperitoneal (i.p.) injection of TMZ (50 
mg/kg/day) in 100 µl DMSO (Sigma-Aldrich, St. Louis, MO) or vehicle control (DMSO) on 
days 6 and 7. For combinational chemoimmunotherapy treatment, tumor-bearing mice were 
treated with TMZ (i.p., 50 mg/kg/day in 100 µl DMSO) or vehicle control (DMSO) on days 6 
and 7, STA9090 (i.p., 25 mg/kg/day in 100 µl DMSO) or vehicle control (DMSO) on days 8 and 
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15, and adoptive transfer of 1-5 x 106 anti-DNA-RP CD8+ T cells (i.v. in the tail vein, in PBS) or 
vehicle control (PBS) on days 9 and 16. Tumor size (in mm2) was determined as the product of 
orthogonal caliper measurements monitored every 3 to 4 days thereafter. Mice were euthanized 
when tumors became ulcerated or they reached a size of 400 mm2, in accordance with IACUC 
guidelines. 
2.7 IFN-γ ELISA 
For tumor recognition assays, splenic CD8+ T cells were co-cultured with melanoma cells, 
negative control EL4 (H-2b; thymoma) or EL4 cells pre-pulsed (for 4h at 37oC) with DNA-RP-
derived peptides (1 µM each) for 48h, after which, cell-free supernatants were harvested and 
assessed for mIFN-γ concentration using a specific ELISA (BD Biosciences). Data are reported 
as mean ± SD of quadruplicate determinations. 
For tumor recognition assays, enriched splenic CD8+ T cells (i.e., single-cell suspensions 
of splenocytes were first obtained from mechanically-disrupted spleen and then CD8+ T cells 
were negatively selected) from vaccinated and naïve mice were co-cultured with freshly-
irradiated (100 Gy at room temperature from a 137Cs irradiator (Gammacell40, Atomic Energy of 
Canada Limited, Mississauga, Ontario, Canada at a dose rate of 0.87 Gy/min) B16 tumor cells 
that had been previously treated with STA9090 (0.1 nM for 12 h) with or without TMZ (50µM 
for 12 h), after which, cell-free supernatants were harvested and assessed for mIFN-γ 
concentrations using a specific ELISA (BD Biosciences). The data are reported as mean ± SD of 
triplicate determinations. 
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2.8 IMMUNOFLUORESCENCE STAINING AND IMAGING 
Tumor tissue samples were embedded in ornithine carbamyl transferase medium (Tissue-Tek; 
Sakura Finetek U.S.A., Inc., Torrance, CA), frozen, and stored at −80°C. Five-micrometer tissue 
sections were prepared using a cryostat microtome, mounted on Superfrost Plus (Fisher 
Scientific, Pittsburgh, PA) slides, and stored at −80°C, followed by immunofluorescence staining 
and microscopy. The following primary antibodies were used for staining sections: rat anti-
mouse CD3, rabbit anti-mouse T-bet (Santa Cruz Biotechnology, San Diego, CA). Secondary 
antibodies included: Cy3-conjugated goat anti-rat Ig and Alexa488-conjugated goat anti-rabbit Ig 
(both from Jackson ImmunoResearch, West Grove, PA). TUNEL staining for detection of 
apoptotic cells was performed using a cell death detection kit (Roche Diagnostics, Indianapolis, 
IN) per the manufacturer’s instructions. All tissue sections were then briefly incubated with the 
nuclear counterstain 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich). After washing, 
sections were then covered in Gelvatol (Monsanto, St. Louis, MO) and a coverslip applied. Slide 
images were acquired using an Olympus Provis microscope (Olympus America, Center Valley, 
PA). Isotype control and specific antibody images were taken using the same level of exposure 
on the channel settings. Metamorph (Molecular Devices, Sunnyvale, CA) software was used for 
labeled cell quantification. 
2.9 FLOW CYTOMETRY 
Single-cell suspensions were directly stained with APC-conjugated anti-CD8 (eBioscience), 
Deep-red dye cell tracker (Thermofisher) and Annexin V-FITC from the apoptosis detection kit 
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Staining kit (Abcam) according to the manufacturer’s instructions. Fluorescently-stained cells 
were assessed using an LSR II flow cytometer (Beckman Coulter), with data analyzed using 
FlowJo software (Tree Star, Inc.). 
2.9.1 Cell cycle analysis by flow cytometry 
Cells were seeded and allowed to attach overnight. Following the relevant treatments 
Temozolomide +/- STA9090, floating and adherent cells were collected at the end of 24 h, 
washed with phosphate-buffered saline (PBS), and fixed with 70% ethanol. The cells were then 
treated with 80 µg/ml RNase A and 50 µg/ml propidium iodide (Invitrogen-Molecular Probes, 
Carlsbad, CA) for 45 min at 37oC. The stained cells were analyzed using a LSR II flow 
cytometer (Beckman Coulter), with data analyzed using FlowJo software (Tree Star, Inc.). 
2.10 STATISTICAL ANALYSES 
Comparisons between groups were performed using a two-tailed Student’s t test or area under 
the curve or one-way Analysis of Variance (ANOVA) with post-hoc analysis, as indicated. All 
data were analyzed using SigmaStat software (Systat Software, USA). Differences with a p-value 
< 0.05 were considered as significant. 
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3.0  TARGETING HSP90 TO COMBAT DRUG-RESISTANT CANCER 
3.1  INTRODUCTION 
Cancer is the second most common cause of death worldwide. From the latest statistics released 
by the International Agency for Research on Cancer (IARC), the global burden of cancer has 
increased to an estimate of 14 million new cases per year, with cancer deaths estimated at up to 
13 million annually. Developing countries are affected disproportionately, with more than 60% 
of new cases and 70% of cancer related deaths occurring in Africa, Asia, Central and South 
America (Globocan 2012, IARC). This situation is made worse in developing nations due to poor 
early detection of disease and the lack of access to first-line, “standard of care” treatments 
including chemotherapy, radiotherapy, targeted immunotherapy and hormone therapy. 
Considering the heterogeneous nature of cancer cells in a given tumor lesion, it is not at all 
surprising that these cell populations rapidly develop compensatory resistance mechanisms to 
circumvent any given specific form of treatment. In order to combat such resistance, many 
studies have considered combining existing, conventional treatments with HSP90i in order to 
destabilize a broad range of client proteins that underlie the acquired drug-resistant phenotype of 
cancer cells. 
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3.2 TARGETING HSP90 IN CANCER THERAPY 
Heat shock protein 90 (HSP90), an ATP-dependent molecular chaperone accounts for about 1-
2% of total protein under normal conditions, but this level increases to 4-6% under stress 
conditions (Hickey et al., 1986). On the other hand, in cancer cells, HSP90 is frequently 
overexpressed and plays an important role in the maintenance of protein conformational 
integrity, stabilization of a number of oncogenic/survival proteins, providing a cytoprotective 
response to hypoxic and acidic microenvironments and preventing their proteasome-mediated 
degradation, thereby supporting tumor progression and metastasis (Whitesell & Lindquist, 2005). 
Most chemotherapeutic agents target a limited number of individual proteins or signaling 
mechanisms, which might lead to the compensatory induction of alternate pro-tumor biologic 
pathways. Use of HSP90i would theoretically lead to a coordinate disruption of multiple 
compensatory pathways that support cancer cell survival and metastasis (Koga et al., 2009). 
Additionally, since HSP90 is highly overexpressed in tumors, this makes HSP90i-based 
intervention somewhat more selective in its site of action (Kamal et al., 2003). As a 
consequence, the use of HSP90i has gained substantial inertia for consideration as a novel cancer 
therapeutic strategy to combat disease resistance that is commonly developed in response to 
conventional cancer treatment modalities. 
3.2.1 Fighting drug-resistance with HSP90i 
To date, chemotherapy and radiotherapy remain the most commonly applied treatments for 
cancer, but these both evoke the development of a high frequency of treatment-resistant disease. 
In order to combat this resistance HSP90 inhibitors are being used in combination with standard 
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of care regimens. The HSP90i, 17-AAG and Geldanamycin have been used in several studies to 
fight developed resistance against commonly-used chemotherapy drugs, such as cisplatin and 
paclitaxel. In almost all cases, the synergistic anti-cancer activity of the drugs has been observed 
(Lu et al., 2012; Solit et al., 2003; Tatokoro et al., 2012; Vasilevskaya et al., 2004). In an in vivo 
study of combination of 17-AAG with cisplatin showed that 17-AAG sensitized nude mice to the 
anti-tumor action of cisplatin treatment (Ohba et al., 2010). After treatment with radiotherapy, 
DNA repair proteins (many of which represent HSP90 clients) become overexpressed, which 
may explain the enhanced therapeutic benefits of combining HSP90i with radiotherapy, leading 
to increased tumor cell death in vitro and in vivo (Schmidt-Ullrich et al., 2003; Dote et al., 2006; 
Jewell et al., 2010; Ha et al., 2011; Stecklein et al., 2012; Guida et al., 2012; Ko et al., 2012; Che 
et al., 2013; Acquaviva et al., 2014; Pennisi et al., 2015). 
Temozolomide (TMZ, aka Temodar) is an alkylating drug. It has been FDA-approved for 
adult patients with refractory anaplastic astrocytoma since 1999 and for adult patients with 
glioblastoma multiforme (GBM) since 2005 (“FDA Approval for Temozolomide - National 
Cancer Institute,” 1999). It is also used to treat melanoma patients. The resistance to TMZ has 
been correlated with overexpression of DNA repair proteins and/or DNA repair pathway 
deficiency (Zhang et al., 2012). Some studies with the older 1st generation HSP90 inhibitor, 17-
AAG to fight the resistance against TMZ in human glioma cells did not induce synergy ( 
Sauvageot et al., 2008; Ohba et al., 2010). However, a study using 17-DMAG on malignant 
glioma cells increased the cytotoxic effect of radiation and TMZ (Choi et al., 2014). 
Even targeted cancer therapies can lead to the development of treatment-resistant disease. 
The anti-tumor activity of Vemurafenib, which inhibits signaling mediated by mutant oncogenic 
BRAF, was improved when combined with the HSP90i such as STA9090 and XL888 
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(Acquaviva et al., 2014). Similar results have been observed for therapeutic combinations that 
incorporate HSP90i (NVP-AUY922, IPI-504, 17-AAG) with anti-HER2 antibodies 
(Trastuzumab) in the setting of human breast cancer (Modi et al., 2011; Scaltriti et al., 2011; 
Wainberg et al., 2013), and HSP90i with imatinib (a KIT inhibitor) in the setting of 
gastrointestinal stromal cancers  (Bauer et al., 2006; Smyth et al., 2012). In addition, ongoing 
studies have also effectively applied HSP90i to increase the sensitivity of breast cancer cells to 
hormone co-therapy. 
Since HSP90i exhibit a degree of tumor selectivity (i.e., accumulation and retention in the 
TME), they should be applied at lower than maximal tolerated doses in combination protocols to 
limit off-target toxicities and to maximize on-target benefits to patients with cancer (Trepel et al., 
2010; Neckers & Workman, 2012). HSP90i represent promising agents for use in combating 
drug-resistant cancers, preferably when used in combination approaches.   
Figure 10. Combating Drug-resistant Cancer with HSP90 Inhibitors. 
Combination with HSP90 inhibitors like Galandamycin, 17-AAG, 17-DMAG, STA9090 increases the sensitivity to 
otherwise resistant chemotherapy, radiotherapy or targeted therapy treatment modalities in cancer patients. 
Therapeutic targeting of HSP90 is predicted to block the pro-tumor impact of multiple oncogenic pathways 
associated with drug-resistant cancer progression and dissemination.  
3.3 RESULTS 
3.3.1 Melanoma develops resistance to the chemo-toxic drug Temozolomide (TMZ) 
To check the efficacy of TMZ treatment, we looked at the effect of this drug on wild-type B16 
melanoma cells. Tumor cells were pre-treated with 50 μM for 14 days in vitro, or established 
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B16 tumors were biopsied from the C57BL/6 mice after two daily doses of TMZ 
(50mg/kg/mouse/day injected i.p.). All cell lines were treated with increasing doses of TMZ 
overnight for 12h starting from 1 μM, 10 μM, 100 μM and 1000 μM. To analyze TMZ-induced 
melanoma apoptosis, tumor cells were stained using an Annexin-V FITC kit and analyzed by 
flow cytometry (Table 5). Results suggest a similar pattern of apoptotic sensitivity amongst 
melanoma cells treated with any dose of TMZ in vitro or in vivo, supporting the conclusion that 
melanoma cells are inherently resistant to TMZ treatment. 
Table 5. B16 Melanoma Develops Resistance to TMZ. 
In, (B) Wild-type B16 melanoma cells, (C) B16 cells pre-treated with 50 μM for 14 days in vitro, (D) established 
B16 tumors were biopsied from the C57BL/6 mice after two daily doses of TMZ (50mg/kg/mouse/day injected 
intra-peritoneally). All cell lines were treated with increasing doses of TMZ overnight for 12h starting from 1 μM, 
10 μM, 100 μM and 1000 μM (A). To analyze TMZ-induced melanoma apoptosis, tumor cells were harvested and 
stained with PI + RNase for 45 minutes at 37oC, or stained with Annexin-V FITC and PI for 5 minutes at RT, prior 
to analysis using flow cytometry. The values in panels B, C and D represent the cumulative percentage of both late 
apoptotic cells and early apoptotic cells. 
(A) 
TMZ dose 
(B) 
% of Total Apoptosis in B16 
tumor cells TMZ treated         
(in vivo) 
(C) 
% of Total Apoptosis in B16 
TMZ pre-treated          
(in vitro) 
(D) 
% of Total 
Apoptosis in B16 
(in vitro) 
UT 1.9 1.6 2.1 
1 µM 3.3 1.3 5 
10 µM 5.2 3.5 3.3 
100 µM 3.8 1.9 3.9 
1000 µM 7.6 2.7 7.9 
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3.3.2 Sensitizing tumors to CT using HSP90i 
In comparison with the treatment groups using TMZ alone, the combination of TMZ with 
STA9090 resulted in a >50-fold increase in tumor cell apoptosis. Hence, the combination therapy 
including HSP90i STA9090 appears to fight intrinsic/acquired tumor cell resistance to TMZ.  
A 
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Figure 11. Treatment of B16 Melanoma Cells with Combined TMZ + HSP90i Results in Superior 
Blockade of G1 to S/G2/M Cell Cycle Transition and Enhanced Cellular Apoptosis In Vitro. 
B16 melanoma cells were left untreated, or they were treated with TMZ (50 µM for 3h) +/- HSP90i STA9090 (25 
µM for 16h) at 37
o
C. Cells were harvested and were fixed with 70% Ethanol overnight at 4oC and then (A) stained
with PI + RNase for 45 minutes at 37
o
C, or (B) stained with Annexin-V FITC and PI for 5 minutes at RT, prior to
analysis using flow cytometry. Q2 represents late apoptotic cells, Q3 represents viable cells and Q4 represents early 
apoptotic cells.  
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3.3.3 CT sensitization with HSP90i leads to loss of the S and G2/M checkpoints and 
increasing apoptotic tumor events  
Preliminary studies were conducted on the B16 murine melanoma cell line treated with 
Temozolomide (TMZ- 50 μM-3 h) in the absence or presence of HSP90i –STA9090 (25 μM -16 
h at 37oC). Cells were harvested and fixed with 70% ethanol overnight at 4oC and then stained 
with PI + RNase (Abcam) for 45 minutes at 37oC prior to analysis using flow cytometry. The 
results suggest that melanoma treatment with the HSP90i STA9090 increases the tumor cell 
sensitivity to CT by limiting the transition from G1 to S and G2/M cell cycle checkpoint and by 
reversing the G2 arrest caused by TMZ (Figure 11).  
 A 
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Figure 12. Treatment of Melanoma Cell Lines with TMZ Results in Upregulated Expression of a 
Subset of DNA-RP In Vitro. 
In A, human (Mel526, Mel624) and murine (BPR20, B16) melanoma cell lines were cultured in the presence of 
TMZ (50 µM) for 12 h at 37oC, at which time, tumor cells were lysed and SDS-PAGE resolved proteins analyzed by 
Western Blotting using specific antibodies reactive against the indicated DNA-RP or control β-actin (as described in 
the Materials and Methods). In B (Ba-Bd). Specific DNA-RP protein bands in blots were quantitated by 
densitometry scanning and normalized to control β-actin as described in the Materials and Methods and all error 
bars reflect SEM, (Ba-MEL526, Bb- MEL624, Bc-BPR20, Bd- B16) with reported values reflective of three 
independent experiments performed in each instance, *, p<0.05. 
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3.3.4 TMZ promotes upregulated expression of a subset of DNA-RP in murine and 
human melanoma cell lines in vitro  
To initially determine whether the genotoxic chemotherapeutic agent, TMZ could alter tumor 
cell expression of DNA-RP, melanoma cell lines were incubated in vitro with TMZ for 48h. 
Using Western Blotting analyses, we observed that TMZ treatment resulted in the coordinate 
increased expression of known DNA-RP (including ATR, PRKDC, MRE11, NBN, RAD50, 
RAD51) when compared with expression of the β-actin control protein by both murine (B16, 
BPR20) and human (Mel526, Mel624) melanoma cell lines, with the only exceptions being for 
PRKDC in Mel526 cells and for RAD51 in Mel624 cells, which may reflect an expected 
heterogenenity in genotype/phenotype amongst metastatic melanomas (Figure 12). 
Figure 13. Melanoma Tumor Develops Resistance to TMZ and Results in Upregulated Expression of 
DNA-RP in vivo. 
In A, C57BL/6 mice bearing established s.c. B16 melanomas (day 7) were treated i.p. with TMZ (50 mg/kg in 
DMSO on days 7-9) or with vehicle control. B, Tumor growth was monitored every 2-4 days through day 19, with 
mean tumor size (+ SD) tumor size reported in mm2. In C, melanoma isolated from the tumor of median size in each 
cohort on day 19 was solubilized and subjected to Western Blotting analysis. D. Specific DNA-RP protein bands in 
blots were quantitated by densitometry scanning and normalized to control β-actin as described in the Materials and 
Methods and all error bars reflect SEM. NS, not significant, *, p<0.05. 
3.3.5 TMZ promotes upregulated expression of a subset of DNA-RP in murine and 
human melanoma cell lines in vivo  
To determine whether similar results could be achieved in vivo, C57BL/6 mice were first 
implanted with B16 melanoma cells s.c. in the right flank, and tumors allowed to establish and 
progress for 6 days. On days 6 and 7, tumor-bearing mice were administered TMZ (50 
mg/kg/day in DMSO) or vehicle control DMSO. As shown in Fig. 13A, TMZ-based therapy 
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slowed B16 melanoma growth for approximately one week, after which tumors developed drug-
resistance and re-established control growth kinetics by day 19 of the experiment. Western 
Blotting analyses of day 19 harvested tumors revealed upregulated expression of DNA-RP in the 
TMZ-treated versus control cohorts (Fig. 13C).  
Figure 14. Effects of TMZ on the Transcription of Melanoma DNA-RP and HSP90. 
The murine (B16) melanoma cell line was cultured in the presence of TMZ (50 µM) for 12 h at 37oC. As described 
in the Materials and Methods, total RNA extracted was reverse transcribed to cDNA and used for qPCR. All mRNA 
expression levels were normalized to the expression of the cellular housekeeping gene product Hprt. Primer 
sequences were selected using Primer-BLAST Genbank and are listed in the Materials and Methods. All error bars 
reflect SEM, *, p<0.05. 
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3.3.6 Effects of TMZ on the transcription of melanoma DNA-RP and HSP90 
Melanoma cells were treated with TMZ (50 µM for 12 h at 37oC) in vitro, prior to cell harvest 
and extraction of cellular mRNA. Levels of DNA-RP transcripts were then quantitated using 
real-time qPCR (Fig. 14). With the exception of PRKDC, melanoma transcript levels for DNA-
RPs were not significantly increased in response to treatment with TMZ. However, we did detect 
an increase in HSP90 mRNA expression after treatment with TMZ, which would support the 
hypothesis that TMZ-associated increases in melanoma expression of DNA-RP may be due to 
post-translational stabilization of these client proteins by TMZ upregulation of melanoma 
expressed HSP90. 
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Figure 15. Genotoxic Chemotherapy agents, but Not BRAFi Dabrafenib, and Radiation Promote Increased 
Expression of DNA-RP RAD50 in B16 Melanoma cells that is Induced to Undergo Degradation by HSP90i in 
Vitro. 
A, The B16 murine melanoma cell line was incubated in the absence or presence of TMZ (50 µM), +/- STA9090 
(25 µM) for 12h or NVP-AUY922 at 37oC, prior to cell solubilization and Western Blotting analysis for the DNA-
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RP RAD50, BRCA2, NBN and ATR versus β-actin control proteins. Specific DNA-RP protein bands in blots were 
quantitated by densitometry scanning and normalized to control β-actin as described in the Materials and Methods. 
B, the B16 murine melanoma cell line was cultured in the absence or presence of TMZ (50 µM), IR 4 Gy , +/- 
NVP-AUY922 at 37oC, prior to cell solubilization and Western Blotting analysis for the DNA-RP RAD51 versus β-
actin control proteins.  C, B16 cell line was incubated in the absence or presence of TMZ (50 µM), Dabrafenib (20 
µM) or Doxorubicin (0.5 µM), +/- STA9090 (25 µM) for 12h at 37oC, prior to cell solubilization and Western 
Blotting analysis for the murine DNA-RP RAD50 versus β-actin control proteins.   
3.3.7 HSP90i promotes the degradation of DNA-RP 
DNA-RPs that were upregulated as a result of TMZ treatment were degraded when treated in 
combination with the HSP90 inhibitors STA9090 and NVP-AUY922. A similar effect was 
observed with the other chemotoxic drug Doxorubicin and radiation as well. But, when treated 
with the BRAF inhibitor Dabrafenib, there was no overexpression of murine DNA-RP RAD50. 
However, when treated in combination with the HSP90i, STA9090, there was degradation.  
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Figure 16. Optimizing the Dose of HSP90 for Combination Therapy of B16 Melanoma. 
In A, C57BL/6 mice bearing established s.c. B16 melanomas (day 7) were treated i.p. with STA9090 (10, 25, 
50, 100, 150 mg/kg in the vehicle as described on days 7-14) or with vehicle control. B, Tumor growth was 
monitored every 3-4 days through day 17, with mean tumor size (+ SD) tumor size reported in mm2. C, When 
STA9090 is used in combination with TMZ, it appears to provide superior anti-tumor efficacy based on inhibited 
tumor growth vs. control treatments **, p<0.05, * =P < 0.1 for combination.  
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3.3.8 Optimal HSP90i dose for combination to fight the TMZ resistance 
To optimize combined therapy using TMZ + HSP90i  STA9090, we first needed to establish an 
optimal dose of HSP90i monotherapy.  In particular,  we wanted to determine the lowest dose 
needed to achieve the greatest degree of therapeutic benefit. It is important to optimize the 
HSP90i dosing to achieve maximal anti-tumor benefits mediated by the immune response, as 
HSP90i can negatively impact DC and T cells when applied in high doses. DC expression of 
MHC class I molecules can also be reduced in the presence of high-dose (1 µM for 24-48h) 
HSP90i in vitro (Bae et al., 2013).  
We initially chose five different doses of  STA9090 10 mg/kg, 25 mg/kg, 50 mg/kg, 100 
mg/kg and 150 mg/kg for analysis. C57BL/6 mice were first implanted with B16 melanoma cells 
s.c. in the right flank and tumors established to palpable lesions by 6 days. On days 7 and 14 
(post-tumor inoculation), tumor-bearing mice were administered different doses of HSP90i 
STA9090 or vehicle control. Ultimately, we selected 25 mg/kg as an optimal dose for future 
experiments as it was the lowest dose that exhibited optimal efficacy against tumor progression 
versus TMZ monotherapy as shown in Fig. 16.  
3.3.9 Identification of immunogenic peptides derived from DNA-RP for use in 
combination immunotherapies  
To determine the impact of TMZ and/or HSP90i on the proteasome-dependent generation of 
MHC I-presented epitopes and consequent CD8+ T cell recognition, we needed to first identify 
immunogenic peptide specific to DNA-RP. 
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For the purposes of investigating the immunogenicity of the 30 peptides described in 
Materials and Methods (Table 4), three groups of 10 pooled peptides were randomly generated 
and used to vaccinate naïve C57BL/6 mice thrice using a weekly schedule. One week after the 
final vaccination, CD8+ splenic T cells cultured with EL4 cells that had been pre-loaded in vitro 
with individual DNA-RP-derived peptides (1 mM) after which, cell-free supernatants were 
harvested and assessed for mIFN-γ concentration using ELISA. 
Figure 17. Analysis and Selection of Immunogenic DNA-RP-derived Peptide Epitopes for CD8+ T 
Cell Recognition. 
A, Out of the 30 peptides synthesized (from Table 4), three groups of 10 peptides each were randomly generated. For 
each group of peptides, an equimolar peptide pool was generated, and each of the three mixtures of peptide 
loaded onto syngenic DC for use as a vaccine applied to naïve (non tumor-bearing) C57BL/6 mice. Overall, mice 
were vaccinated s.c. 3 times on a weekly basis with IL-12 gene-modified DC (DC.IL12, which promote CD8+ T cell 
responses without the need for CD4+ T helper epitopes pulsed with an equimolar pool of DNA-RP peptides (Fig. 
17A). Control mice were vaccinated with DC.IL12 alone. One week after the final DC-based vaccine, the mice were 
euthanized and CD8+ splenic T cells cultured with syngenic (H-2b) antigen-presenting cell line EL4, or with EL4 
cells that had been pre-loaded in vitro with individual DNA-RP-derived peptides (1 mM) after which, cell-free 
67 
supernatants were harvested and assessed for mIFN-γ concentration using a specific ELISA. Data are reported as 
mean ± SEM of triplicate determinations. (panel B-Group1, C-Group 2, D-Group 3) .   
3.3.9.1 Mice vaccinated against DNA-RP developed CD8+ T cells reactive against specific 
DNA-RP peptides based on IFN-γ secretion as quantitated by ELISA  
Amongst the peptides (Table 4 in Methods) analyzed in Group 1, PRKDC1187-1194, 
PRKDC620-628, MRE11109-116, MRE11208-216 proved to be most immunogenic, with NBN273-281 
also better recognized by T cells after specific vaccination. In group 2, the RAD5158-66, 
RAD51212-219, RAD501180-1187, RAD50391-399, ATR1390-1397, and XRCC6483-491 were identified as 
immunogenic. In group 3, only the BRCA22848-2856 peptide displayed evidence of 
immunogenicity. Based on results obtained in  3 independently performed experiments, I 
selected the 9 most immunogenic peptides listed in Table 5 (i.e., RAD5158-66 , RAD51212-219  
RAD501180-1187, RAD50391-399, ATR1390-1397, PRKDC620-628, MRE11109-116, MRE11208-216 NBN273-
281) for use in subsequent studies involving combination chemoimmunotherapies. TMZ-inducible 
DNA-RP contains immunogenic peptides recognized by CD8+ T cells in wild-type C57BL/6 
mice. 
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Table 6. DNA-RP Peptides selected for Combination ACT. 
Figure 18. Vaccination against DNA-RP-derived Peptides Elicits Specific CD8+ T Cells in Mice that 
Preferentially Recognize TMZ/HSP90i-conditioned B16 Melanoma Cells In Vitro. 
69 
To generate antigen-specific CD8+ T cells reactive against DNA-RP, we first used a web-based algorithm to select 
for those peptides most likely to be coordinately proteasome-processed and MHC class I-presented in the H-2b 
C57BL/6 strain of mice (Table 5). Naïve mice were vaccinated s.c. a total of 3 times on a weekly regimen with 
syngenic DC.IL12 cells (i.e., DC engineered to produce mIL12p70 protein) that were loaded with an equimolar pool 
(1 µM for each peptide) of the chosen peptides (panel A schema, with additional detail in Materials and Methods). 
Splenic CD8+ T cells isolated from vaccinated or control, naïve mice were then co-cultured at an effector-to-target 
cell ratio of 5:1 for 48h with EL4 (H-2b, thymoma) cells pulsed (for 4h at 37oC) with individual DNA-RP peptides 
(1 µM, panel B), or against negative control EL4 cells, untreated B16 melanoma cells or B16 cells pre-treated with 
TMZ +/- HSP90i (panel C). Cell-free supernatants were then analyzed for mIFN-γ concentration using a cytokine-
specific ELISA. Results are reflective of 3 independent experiments performed in each instance and are reported as 
mean ± SEM of triplicate determinations. *p < 0.05 vs. EL4 or B16 control cells.  
3.3.9.2 Splenic T cells from mice vaccinated against pooled DNA-RP-derived peptides 
recognize B16 melanoma cells better after treatment with TMZ + HSP90i 
As shown in Fig. 18A, mice vaccinated against DNA-RP developed CD8+ T cells 
reactive against specific DNA-RP peptides based on IFN-γ secretion quantitated by ELISA. 
Amongst the peptides (Table 6) analyzed, the RAD501180-1187 peptide appeared most 
immunogenic in pooled vaccine formulations, with the peptides ATR200-208, PRKDC620-628, 
MRE11109-116, MRE11208-216, NBN273-281, RAD50391-399, RAD5158-66 and RAD51212-219 also 
recognized differentially by vaccinated vs. control CD8+ T cells (Fig. 18B). In contrast, the 
peptides ATR1390-1397, PRKDC1187-1194 and NBN355-363 failed to elicit statistically-significant, 
antigen-specific CD8+ T cell responses in vaccinated mice, *p < 0.05. 
Splenic T cells from mice vaccinated against pooled DNA-RP-derived peptides were also 
used as effector cells against target cells including the negative control EL4 thymoma, untreated 
B16 melanoma cells, and B16 melanoma cells pre-treated with TMZ (to upregulate DNA-RP) 
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+/- HSP90i (STA9090, to conditionally promote the loading of MHC class I complexes with 
DNA-RP-derived peptides generated via proteasome degradation). As shown in Fig. 18C, anti-
DNA-RP-primed T cells, but not naïve T cells, were capable of preferentially recognizing B16 
melanoma cells treated with TMZ + HSP90i. 
3.4 SUMMARY 
We found that melanoma cell lines are intrinsically refractory to the cytotoxic effects of TMZ, 
but that HSP90i could be used to sensitize these tumors to TMZ-induced apoptosis in vitro. 
When observing the cell cycle patterns of treated melanoma cells, sensitization might be the 
result of abrogating the transition from G1 to S phase and due to the reversal of G2 checkpoint 
loss caused by TMZ. Although TMZ was only a weak promoter of tumor cell apoptosis when 
used as a single-agent, this chemotherapy drug effectively stimulated melanoma cells to increase 
their expression of key DNA repair proteins involved in the G1 and G2/M cell cycle phases, 
including ATR, CHEK2, PRKDC, MRE11, NBN, RAD50 and RAD51. Since TMZ only 
promoted increased DNA-RP protein, but not transcript, expression, and we found that TMZ 
treatment led to augmented transcription of HSP90, we hypothesize that TMZ-induced HSP90 
may be stabilizing DNA-RP client proteins. This would lead to the prediction that the HSP90i 
destabilize tumor cell expression of these DNA-RP, making them more susceptible to the 
cytotoxic action of TMZ (as we observed in combined experiments). We also determined that 
mice vaccinated against DNA-RP developed CD8+ T cells reactive against RAD50, RAD51, 
PRKDC, MRE11, NBN and ATR. These peptides enabled us to assess combination 
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chemoimmunotherapy (TMZ +/- HSP90i +/- DNA-RP targeted immunotherapy) for melanoma-
bearing mice.  
 Proposed schema for improved recognition of TMZ/HSP90i-conditioned melanoma 
cells by therapeutic anti-DNA-RP CD8+ T cells. Melanoma cells, even if briefly treated with 
TMZ, upregulate expression of DNA-RP that represent clients of the HSP90 chaperone 
complex. Subsequent administration of HSP90i (such as STA9090/Ganetespib) results in the 
proteasome-dependent degradation of DNA-RP, providing a conditional source of peptides for 
presentation in MHC class I complexes on the melanoma cell surface. Once expressed on 
the tumor cell surface, these complexes are capable of being recognized by DNA-RP-reactive 
CD8+ T cells that may be induced in vivo by active, specific vaccination and applied in 
ACT-based treatment approaches. 
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4.0  HSP90 INHIBITION ENHANCES THE ANTI-TUMOR EFFICACY OF 
COMBINATION CHEMOIMMUNOTHERAPY TARGETING DNA REPAIR 
PROTEINS 
4.1 ABSTRACT 
Although melanoma is generally considered to be resistant to genotoxic chemotherapeutic 
agents, we report that treatment with Temozolomide (TMZ) induces murine and human 
melanoma cell lines to upregulate expression of DNA repair proteins (DNA-RP) that represent 
HSP90 clients in vitro and in vivo. TMZ-induced DNA-RP can then serve as protein substrates 
for proteasome-dependent generation of MHC class I-presented peptide epitopes upon 
subsequent administration of the HSP90 inhibitor STA9090 (Ganetespib). Notably, pre-
conditioning of progressively growing B16 melanomas in C57BL/6 mice with systemic TMZ + 
STA9090 treatment sensitizes melanoma cells to the anti-tumor action of adoptively-transferred 
DNA-RP-specific CD8+ T cells. The efficacy of combination chemoimmunotherapy integrating 
TMZ, STA9090 and antigen-specific adoptive T cell transfer was associated with superior levels 
of Type-1 CD8+ TIL in treated tumors and more expansive areas of tissue apoptosis within the 
tumor microenvironment. These data support the possible translation of such combination 
treatment strategies into the clinic for the treatment of patients with melanoma.  
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4.2 INTRODUCTION 
Melanoma is the 5th most common form of cancer in the United States and is one of three cancer 
types that continue to increase in incidence (Siegel et al., 2013). Metastatic melanoma, the most 
dangerous form of skin cancer, responds poorly to conventional chemotherapy, with a median 
overall survival of less than one year (Guida et al., 2012). Although the results of several recent 
clinical trials support the potent anti-melanoma activity of immune checkpoint inhibitors (i.e., 
anti-CTLA4, anti-PD1 or anti-PD-L1 antibodies) as standard of care, few patients receive 
durable treatment benefit (Phan et al., 2003; Brahmer et al., 2010; Cohen & Sznol, 2015). As a 
consequence, there remains a clear need for the continued development of novel, effective 
second-line therapy options for such patients. 
Chemotherapeutic agents, such as TMZ, cause “incorrectable” DNA lesions in treated 
tumor cells, most commonly DNA double-strand breaks (Fojo, 2001; Luqmani, 2005; Khan et 
al., 2011). Moderately-impacted tumor cells may amplify gene products associated with DNA 
repair in order to maintain cellular viability, leading to a state of acquired chemotherapy 
resistance (Kauffmann et al., 2008). In the melanoma setting, DNA-RP (such as ATM, CHEK2, 
ATR, CHEK1, BRCA1, BRCA2, MRN complex proteins (MRE11, RAD50, NBN), XRCC6, 
XRCC5, RAD51, PRKDC) are transcriptionally overexpressed in a disease stage-associated 
manner in association with chemotherapy-resistance and poor overall survival (Schmidt-Ullrich 
et al., 2003; Dote et al., 2006; Jewell et al., 2010; Taipale et al., 2010; Ha et al., 2011; Stecklein 
et al., 2012; Guida et al., 2012; Ko et al., 2012; Che et al., 2013; Acquaviva et al., 2014; Pennisi 
et al., 2015).  
Notably, tumor cell overexpression of DNA-RP is also sustained post-translationally via 
the stabilizing action of chaperone molecules, such as heat shock protein-90 (Dote et al., 2006; 
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Taipale et al., 2010; Ha et al., 2011; Ko et al., 2012; Stecklein et al., 2012; Che et al., 2013; 
Acquaviva et al., 2014;), a highly-abundant molecule in the cancer proteome (Whitesell & 
Lindquist, 2005). HSP90 forms the core of a super-chaperone machine consisting of HSP70, 
HSP40, HIP and HOP, which extends the molecular lifespan of a growing list of client proteins, 
including signaling protein kinases, transcription factors, DNA-RP and other cytosolic or nuclear 
proteins in their functionally mature and active conformations (Taipale et al., 2010). While most 
targeted therapy agents antagonize 1-2 individual proteins or signaling pathways, which might 
lead to the selection of compensatory pro-oncogenic pathways by adapting tumor cells, HSP90i 
would be expected to coordinately disrupt multiple DNA-RP clients (and a range of pro-tumor 
signaling pathways), supporting the survival/progression of heterogeneous populations of cancer 
cells (Koga et al., 2009). Since HSP90i are known to promote the conditional degradation of 
client proteins via the proteasome pathway (Whitesell & Lindquist, 2005; Taipale et al., 2010; 
Acquaviva et al., 2014), a major conduit for immunogenic peptides presented by MHC class I 
molecules to CD8+ T effector cells (Goldberg et al., 2002), we reasoned that melanoma cells 
conditioned by genotoxic chemotherapy agents and then treated with HSP90i might represent 
preferred targets for DNA-RP-specific CD8+ T cells in vivo.  
Data developed in both murine and human melanoma models suggest that tumor 
expression of DNA-RP is upregulated in the presence of TMZ, and that tumor overexpressed 
DNA-RP can then be induced to undergo proteasome-dependent degradation after treatment with 
the HSP90i STA9090, in support of the superior anti-tumor efficacy of adoptively-transferred 
CD8+ T cells specific for DNA-RP that constitute HSP90 client proteins. The anti-tumor benefit 
of the combination immunotherapy was associated with enhanced Type-1 T cell infiltration into 
tumor lesions, with higher levels of tumor cell apoptosis in vivo, and with the upregulated 
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expression of inflammation-responsive PD-L1 by tumor/stromal cells in therapeutic tumor 
microenvironment. Overall, these studies serve as a foundation for the design and 
implementation of novel chemo-immunotherapeutic strategies for translation into the clinic for 
the treatment of patients with advanced-stage melanoma or alternate cancer types that exhibit 
intrinsic or developed resistance to genotoxic chemotherapies. 
4.3 RESULTS 
4.3.1 DNA-RP overexpression in TMZ-conditioned melanomas is stabilized by HSP90 and 
subject to proteasome-dependent degradation in the presence of HSP90i  
Since members of the DNA-RP family of proteins have been previously suggested to represent 
HSP90 clients, we next analyzed whether expression of DNA-RP by wild-type and TMZ-
conditioned B16 (murine) and Mel526 (human) cells was sensitive to treatment with the HSP90i 
STA9090 in vitro. As shown in Fig. 19, we found that both intrinsic and TMZ-induced DNA-RP 
expression was strongly downregulated after co-culture with STA9090, with these effects 
partially antagonized by the inclusion of the proteasome inhibitor MG132. These data support 
the conclusion that at least a fraction of melanoma DNA-RP undergo proteasome-dependent 
degradation when treated with HSP90i, theoretically providing a therapy-associated source of 
MHC class I presented peptides for enhanced CD8+ T cell recognition. 
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Figure 19. TMZ-upregulated DNA-RP in Murine and Human Melanoma Cell Lines are Degraded in 
the Presence of HSP90i STA9090 in a Proteasome-dependent Manner. 
Murine B16 and human Mel526 melanoma cells were pre-treated with TMZ (50 µM) for 3h at 37oC, before 
subsequent culture in the absence or presence of HSP90i (50 µM) and/or MG132 (10 µM) at 37oC for an additional 
12h. Cells were then solubilized and DNA-RP proteins analyzed by Western Blotting panel A. Specific DNA-RP 
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protein bands in blots were quantitated (panel B) by densitometry scanning and normalized to control β−actin as 
described in the Materials and Methods and is reported as mean + SEM. Examples of treatment changes in DNA-RP 
expression are provided for RAD50 in the B16 (panel C) and NBN in Mel526 (panel D) melanoma cell lines. 
Results are reflective of three independent experiments.  *p < 0.05. 
Figure 20. Combination TMZ/HSP90i + DNA-RP Primed ACT Provides Superior Anti-Tumor Efficacy vs. 
either Chemo- or Immune-Monotherapy. 
As depicted in the panel A schema, C57BL/6 mice were injected s.c. in their right flanks with 105 B16 melanoma 
cells and tumor allowed to establish for 6 days. All animals were conditioned with TMZ (50 mg/kg) for 2 days, 
before then randomizing them into 5 mice/cohort (i.e., each group with a comparable mean tumor size of 
approximately 40-50 mm2) on day 8. Tumor-bearing mice were then treated with HSP90i (STA9090; 25 mg/kg, i.p., 
on days 8 and 15) or vehicle control (DMSO) +/-  ACT (106 splenic CD8+ T cells non-primed or primed with DNA-
RP peptides injected i.v. into the tail vein on days 9 and 16). Tumor growth was then monitored every 3-4 days 
through day 30 (euthanasia) and is reported as mean + SD tumor size in mm2 (B); *p < 0.1 vs. all other cohorts 
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(ANOVA and area under the curve). Animals bearing day 13 tumors of median size were subsequently harvested 
and analyzed by flow cytometry (panel C, for CD8+ TIL) as outlined in the Materials and Methods.  
4.3.2 Combined TMZ/HSP90i + anti-DNA-RP vaccination provides superior anti-
melanoma efficacy vs. single modality treatment in vivo  
Based on the operational paradigm that TMZ + HSP90i treatment results in upregulation of 
DNA-RP followed by enhanced processing and MHC class I presentation of DNA-RP-derived 
peptides, we next evaluated whether this conditional regimen would facilitate the anti-tumor 
action of ACT using DNA-RP-specific CD8+ T cells induced by syngeneic DC pulsed with 
immunogenic DNA-RP-derived peptides that had previously been identified in Fig. 18.  Tumor-
bearing mice were treated as shown in Fig. 20A, and then monitored for tumor growth over time, 
with animals harboring median-sized tumors euthanized on day 30 for assessment of immune 
cell infiltration. We observed that the group treated with TMZ/HSP90i + ACT had the slowest 
growing tumors (Fig. 20B) and the highest degree of CD8+ T cell infiltration into tumors (Fig. 
20C) when compared to all other cohorts of treated animals.   
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Figure 21. Combined TMZ/HSP90i + ACT Therapy of Established B16 Melanomas is Superior to 
Chemo- or ACT-Monotherapy in Reducing Tumor Growth In Vivo. 
As depicted in the panel A schema, C57BL/6 mice were injected s.c. in their right flanks with 105 B16 melanoma 
cells and tumor allowed to establish for 6 days. All animals were conditioned with TMZ (50 mg/kg) for 2 days, 
before then randomizing them into 8 mice/cohort (i.e., each group with a comparable mean tumor size of 
approximately 40-50 mm2) on day 8. Tumor-bearing mice were then treated with HSP90i (STA9090; 25 mg/kg, i.p., 
on days 8 and 15) or vehicle control (DMSO) +/- ACT (106 splenic CD8+ T cells harvested from DNA-RP peptide 
vaccinated mice as in Fig. 18A injected into the tail vein on days 9 and 16). Tumor growth was then monitored 
every 3-4 days through day 30 (euthanasia) and is reported as mean + SD tumor size in mm2 (B); *p < 0.05 vs. all 
other cohorts (ANOVA and area under the curve). Animals bearing day 30 tumors of median size were subsequently 
harvested and analyzed for expression of DNA-RP MRE11 by Western Blotting (C) and for cellular apoptosis by 
TUNEL staining as imaged and quantitated and is reported as mean + SEM, using fluorescence microscopy and 
Metamorph software, per the Materials and Methods (D). *p < 0.05 vs. TMZ alone; **p < 0.05 vs. all other cohorts 
(ANOVA). All results are reflective of three independent experiments performed in each instance. 
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4.3.3 Combination immunotherapy using TMZ/HSP90i + ACT using CD8+ T cells 
reactive against DNA-RP provides superior anti-tumor efficacy versus component 
monotherapies 
Given the ability of TMZ to enhance melanoma expression of DNA-RP and for the HSP90i 
STA9090 to promote the subsequent proteasome degradation of these client proteins, we 
hypothesized that such pre-conditioning would sensitize progressively growing B16 melanomas 
to the anti-tumor action of adoptively-transferred CD8+ T cells reactive against DNA-RP-derived 
peptide epitopes. For these experiments, B16 melanomas were established s.c. in C57BL/6 mice 
for 6 days, at which time they received i.p. TMZ conditioning for 2 consecutive days, followed 
by weekly i.p. administration of STA9090 (25 mg/kg; or the DMSO vehicle control) beginning 
on days 8 and 15 post-tumor inoculation (Fig. 21A). One day following treatment with the 
HSP90i or DMSO (i.e., days 9 and 16 post-tumor inoculation), the mice received i.v. injection of 
1 x 106 fluorescently (Deep red dye)-labeled anti-DNA-RP CD8+ T cells (isolated from the 
spleens of naïve syngenic mice vaccinated against pooled DNA-RP peptides as in Fig. 21) in 
their tail veins. As shown in Fig. 21B, while treatment of TMZ-conditioned B16-bearing mice 
with either STA9090 alone or anti-DNA-RP CD8+ T cells alone failed to impact tumor growth, 
the combined therapy (STA9090 + adoptive cell therapy; ACT) resulted in significantly reduced 
tumor progression. As expected, therapeutic intervention with TMZ/STA9090 (+/- ACT) led to a 
reduction in day 17 tumor expression of DNA-RP (such as MRE11) in vivo (Fig. 21C). 
Interestingly, the combined TMZ + ACT treatment protocol also resulted in less MRE11 
expression in tumors (when compared to the TMZ only treatment cohort of mice (Fig. 21C), 
possibly due to immune selection by vaccine-induced anti-MRE11 CD8+ T cells used for ACT. 
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We also observed the greatest degree of cellular apoptosis within tumors of mice treated with 
TMZ/HSP90i + ACT (Fig. 21D; p < 0.05 vs. all other cohorts, ANOVA).  
Figure 22. Combined TMZ/HSP90i + ACT Therapy of Established B16 Melanomas Promotes Superior 
Tumor Infiltration by Type-1 CD8+ TIL. 
Day 30 harvested tumors were analyzed by flow cytometry (panel A, for CD8+ TIL and Deep red dye+ CD8+ TIL) 
or fluorescence microscopy (B, for Tbet+CD3+ TIL) as outlined in Materials and Methods. Results are reflective of 3 
independent experiments performed and all error bars reflects mean + SEM. **p < 0.05 vs. all other cohorts 
(ANOVA). 
4.3.4 Combined TMZ/HSP90i + specific ACT therapy of established B16 melanomas 
promotes superior tumor infiltration by Type-1 CD8+ TIL  
Additional analyses of day 17 melanoma tissues using flow cytometry and immunofluorescence 
microscopy revealed that combined TMZ/STA9090 + anti-DNA-RP T cell-based ACT was 
associated with the superior infiltration of tumors by Deep red dye+ ACT T cells (Fig. 22A) and 
Tbet+CD8+ T cells (Fig. 22B). In groups treated with STA9090, higher levels of CD8+ T cells 
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were observed in tumors vs. spleens, suggesting that HSP90i facilitates tumor infiltration by T 
cells, with similar results observed in experiments using Deep red dye+ ACT T cells. The 
combination of HSP90i and ACT led to a >30-fold increase in labeled TIL vs. treatement with 
ACT alone, supporting a role for STA9090 in improved tumor infiltration by CD8+ T cells.  
4.4 DISCUSSION 
The major novel findings in Chapter 4 are that DNA-RP expressed by melanoma cells can be 
upregulated by genotoxic agents, such as TMZ, and can then be conditionally-induced to 
undergo proteasome-dependent degradation by HSP90i, leading to improved recognition of 
melanoma cells by therapeutic anti-DNA-RP specific CD8+ T cells in vitro and in vivo. As a 
consequence, despite the known inherent resistance of human melanomas to TMZ (Alvino et al., 
2006; Mhaidat et al., 2007; Rietschel et al., 2008) which we also observed in vivo in B16 models, 
in Chapter 3), this agent can be used to “accumulate” higher levels of DNA-RP to serve as a 
supply of immunogenic peptides in combination therapies integrating HSP90i such as STA9090. 
This effect was not restricted to TMZ, as we also observed that the genotoxic anthracycline 
Doxorubicin (Supino et al., 1988; Ramachandran et al., 1993), but not the BRAFi Dabrafenib, 
was also able to promote elevated expression of DNA-RP in treated melanoma cells that were 
consequently susceptible to HSP90i-induced degradation. 
The finding that we could readily induce autoimmune CD8+ T cell responses against non-
mutated “self” peptides derived from DNA-RP using DC-based vaccines is consistent with 
previous reports supporting the ability of melanoma lineage antigen (MART1, PMEL, tyrosinase 
and others)-based vaccines to activate a low-to-moderate avidity T cell repertoire in mice and 
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humans, despite the host’s apparent operational “self-tolerance” to such antigens (Schreurs et al., 
2000; Slingluff et al., 2006; Rao et al., 2012). Although we only analyzed the capacity of 
combination TMZ/HSP90i-based therapy to improve the anti-tumor efficacy of adoptively-
transferred anti-DNA-RP CD8+ T cells in our melanoma treatment modeling, it would be 
anticipated that this drug combination would also improve the therapeutic benefits associated 
with active specific vaccination against DNA-RP (using antigen-loaded Type-1-polarized DC or 
alternate strategies). Such analyses will be pursued in future studies extended to include alternate 
genotoxic agents (including DOX known to promote tumor “immunogenic cell death” (Obeid et 
al., 2007)) and additional inhibitors of HSP90 (including alternate in-clinic HSP90i that affect 
ATP-binding (Butler et al., 2015), as well as, HDACi known to inhibit HSP90 function via 
altered acetylation of regulatory lysine residues (Bali et al., 2005; Scroggins et al., 2007; 
Kekatpure et al., 2009). Although no evidence for pathologic autoimmunity was observed in our 
ACT modeling, it will be important to monitor mice vaccinated against DNA-RP in future 
experiments for deleterious autoimmune sequelae, particularly in combination approaches 
designed to promote strong inflammatory responses (Gilboa, 2001; Phan et al., 2003; Kong et al., 
2009; Brahmer et al., 2012; Weber et al., 2015).   
Our findings also support the ability of combined TMZ/HSP90i + ACT-based therapy to 
promote enhanced infiltration of melanomas by Type-1 (Tbet+) CD8+ T cells (including the ACT 
population of deep red dye-labeled CD8+ T cells) in association with improved treatment 
outcome, and are consistent with several recent reports supporting higher numbers of CD8+ TIL 
as a predictive biomarker for patient benefit to immunotherapy (Rusakiewicz et al., 2013; 
Berghoff et al., 2015; Noble et al., 2016; Tokito et al., 2016). However, CD8+ T effector TIL 
produce IFN-γ, which can promote upregulated expression of immune checkpoint molecules 
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such as PD-L1 (Mandai et al., 2016; Tokito et al., 2016) in the TME. PD-L1 agonism of PD-1 on 
TIL can reduce the viability and anti-tumor functionality of these protective T cell populations in 
vivo (Brahmer et al., 2012). Hence, future studies should be designed to determine whether the 
anti-PD-L1 and/or anti-PD-1 immune checkpoint inhibitors can further improve the anti-tumor 
efficacy of our current combination chemoimmunotherapy approach.  
The ability of HSP90i to enhance recognition of melanoma target cells by CD8+ T cells 
might yet be suboptimal, since cellular expression of the HSP70 chaperone molecule is known to 
be increased in response to HSP90i (Whitesell et al., 2003), and HSP70 can substitute for HSP90 
in stabilizing client proteins (Cavanaugh et al., 2015). Such complementation in the molecular 
salvage pathway might limit the pool of DNA-RP accessible for proteasome processing, and 
hence, the amount of DNA-RP-derived peptides capable of being presented to anti-DNA-RP 
CD8+ T cells. As a consequence, it might be anticipated that transient coordinate application of 
HSP70i + HSP90i might result in more robust anti-tumor activity mediated by DNA-RP-specific 
T effector cells, as well as, to a greater degree of tumor cell apoptosis based on reduced levels of 
functional DNA-RP in treated tumor cells. Despite concerns for systemic toxicities that might 
arise in such combination regimens, these treatment protocols will be carefully evaluated in 
future studies.  
In conclusion, we believe that these translational results support the design of new 
chemoimmunotherapeutic options for patients with melanoma or alternate advanced-stage forms 
of solid cancer that exhibit chemotherapy-resistance and/or that fail current first-line therapies 
(including immune checkpoint blockade). 
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5.0  DISCUSSION AND SUMMARY 
Cancer remains a major public health threat worldwide. Estimated new cancer cases diagnosed in 
the US in 2016 alone will be 1,685,210. Overall cancer-related deaths in the US in 2016 are 
expected to be 595,690, making cancer the second leading cause of death in this country, 
exceeded only by heart disease (Cancer Facts and Figures, 2016). Although there was ~20% 
improvement in 5-year relative survival rate for all cancers diagnosed from 2005-2011 (69%) in 
comparison to 1975-1977 (4%) due to early diagnosis of certain cancers and improvements in 
targeted therapeutics, there remains a critical need to develop more effective treatment options 
for patients afflicted with cancer. In this regard, even though the combination 
chemoimmunotherapy that we developed was applied to melanoma models, it is clearly 
applicable to virtually any form of cancer based on the essential nature of DNA-RP (and HSP90) 
to general tumor cell survival/progression. Having said this, melanoma is a common disease that 
accounts for 75% of skin cancer-related deaths in the US each year. The incidence of cutaneous 
melanoma has been steadily increasing over the past three decades, primarily amongst adults 
over 50 years of age (Cancer Facts and Figures, 2016; Siegel et al., 2016). Like other forms of 
cancer, melanoma has evolved numerous mechanisms that confer resistance to conventional 
cancer therapeutic, making melanoma a perfect model in which to test the hypotheses of this 
study. 
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Despite recent advancements in cancer immunotherapy and targeted therapies, many 
patients worldwide still receive chemotherapeutic agents as first-line treatment. Chemotherapy 
has been used extensively in the setting of cancer treatment since the 1940s. Seventy years later, 
however, such therapies have not demonstrated profound survival benefits when applied as 
single agents, due to the rapid development of treatment-refractory disease. Hence, the vast 
majority of drug-resistant patients require effective second-line therapies that are capable of 
conferring improved clinical benefits (Fojo, 2001; Chabner & Roberts, 2005). A patient’s tumor 
mass represents a highly heterogeneous population of malignant cells, with only a subset of these 
cells typically sensitive to the action of a given monotherapy. Treatment-resistant tumor clones 
readily persist and expand, making any initial therapeutic benefits exceedingly transient in 
nature, with progressive tumors likely to exhibit even more aggressive characteristics (i.e., 
invasion, metastasis, immune suppressive capacity (Persidis, 1999; Hanahan & Weinberg, 2011; 
Rebucci & Michiels, 2013). 
Tumors adopt several mechanisms to resist the cytotoxic action of chemotherapeutic 
agents. These include the accumulation of activating mutations of oncogenes or inactivating 
mutations of tumor suppressor genes, increased drug export pathways to lower intracellular drug 
concentrations, limiting or circumventing programmed cell death pathways to evade apoptosis, 
and by taking advantage of the DNA damage response (Rebucci & Michiels, 2013). Amongst 
many potential mechanisms underlying cancer resistance to genotoxic chemotherapy agents, 
overexpression of DNA repair proteins has been identified as a dominant player. All 
conventional chemotherapeutic drugs induce tumor cell death by causing accumulated DNA 
damage that eventually leads to apoptosis. Such therapy-induced genetic alterations can be 
counteracted by the action of “normal” DNA repair pathways that are accentuated in cancer cells 
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based on the intrinsic overexpression of DNA-RP (Yoshimoto et al., 2012). A study assessing 
the genetic profile of primary melanomas progressing to metastatic disease over a 4-year period 
documented a striking correlation with upregulated expression of DNA-RP in cancer cells. 
Furthermore, such overexpression of DNA-RP has been correlated to the resistance of metastatic 
melanoma to both chemo- and radiotherapy (Kauffmann et al., 2008). Such clinical associations 
have led to the targeting of DNA repair pathways as a therapeutic strategy in the cancer setting 
(Fojo, 2001). 
Many small molecule inhibitors of DNA repair pathways have been developed as cancer 
therapeutics. PARP-inhibitors have been evaluated in phase I/II clinical trials either as a 
monotherapy or in combination with TMZ or other genotoxic drugs (Helleday et al., 2008). 
Though PARP is involved in base excision repair, it is not solely involved in DNA repair. There 
are other clinical trials involving small molecule inhibitors targeting proteins that are solely 
involved in the process of DNA repair. Beyond PARP1 as a therapeutic target in the base 
excision repair pathway, inhibitors targeting APE1, FEN1 are currently under investigation in 
translational/clinical models. Mismatch repair (MMR) pathway inhibitors targeting MLH1 and 
MSH2, as well as, Nucleotide Excision repair inhibitors targeting multiple proteins within the 
pathway (such as  XPA, RPA) are currently under investigation as well (Kelley et al., 2014). For 
more lethal DSB lesions, alkylating agents such as TMZ (which modifies nitrogen atoms in the 
DNA ring causing a mismatch repair that is not repaired by MMR) is being applied to induce 
tumor cell death by provoking DSB. Indeed, the status of DSB repair activity appears to 
determine the comparative anti-tumor efficacy of genotoxic chemotherapy drugs (Yoshimoto et 
al., 2012). Small molecule inhibitors are being developed to target DSB repair pathway proteins, 
including RAD51and RPA in HR, in addition to PRKDC, PNKP, and DNA-Ligase 4 in NHEJ 
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(Tan & Lynch, 2013; Kelley et al., 2014). Even though translational research and clinical trials 
have validated the therapeutic effectiveness of specific DNA-RP inhibitors, the utility of these 
agents becomes more challenging as the disease stage progresses and the TME becomes 
increasingly hypoxic, making cancer cells more prone to DNA mutations linked to 
chemotherapy-resistance (Helleday et al., 2008; Kinsella, 2009). This suggests that the action of 
genotoxic chemotherapies will be optimized under conditions that coordinately counteract 
multiple tumor DNA repair pathways and replicative stressors in the TME (i.e., hypoxia).  
This is where HSP90 inhibitors come into play. HSP90 along with other molecular co-
chaperones have hundreds of cellular client proteins that play roles in many of the “hallmarks of 
cancer” first set forth by Hanahan and Weinstein (Hanahan & Weinstein, 2000) including self-
sufficiency in growth signals, insensitivity to growth-inhibitory mechanism, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue 
invasion and metastasis (Hanahan & Weinberg, 2011; Miyata et al., 2013). Antagonizing HSP90 
function in tumor cells is an “economical” therapeutic option, as this chaperone molecule is 
preferentially overexpressed in cancer cells where it coordinately stabilizes a number of DNA-
RP. This provides confidence for the safety profile of HSP90i in cancer patients and for the 
ability of these agents to interrupt the evolution of treatment-refractory disease amongst 
heterogeneous tumor cell populations. Notably, HSP90 expression levels in tumor cells have 
been reported to be prognostic of decreased survival in breast cancer patients (Pick et al., 2007). 
Another study showed an induction of HSP90 expression in malignant melanoma and melanoma 
metastasis (Becker et al., 2004). Furthermore, the authors reported that the activity of HSP90 in 
the TME is increased via post-translational modification, with tumor associated antigens 
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exhibiting higher ATPase activity ( Kamal et al., 2003; Becker et al., 2004; Barrott & Haystead, 
2013).  
HSP90 inhibitors continue to be investigated in the clinical setting, with 2nd-generation 
small molecule HSP90i, such as STA9090 and NVP-AUY922 demonstrating superior anti-tumor 
effectiveness when compared to 1st-generation geldanamycin (GA)-based drugs. In contrast to 
GA, 2nd-generation agents are not confounded by cardiovascular and hepatic toxicity issues. 
Furthermore, these newer agents (such as STA9090) have over 100-fold greater affinity for 
tumor- vs. normal cell-associated HSP90 complexes, providing drug-selectivity for diseased 
tissue (Kamal et al., 2003; Wang et al., 2010). Interestingly, STA9090 appears to exhibit greater 
anti-tumor activity when compared with GA as a single modality therapy, and a randomized 
phase II study of STA9090 administered in combination with Docetaxel (an anti-mitotic 
chemotherapy drug) as second-line therapy for advanced non-small-cell lung cancer patients 
showed favorable progression-free survival and overall survival in the adenocarcinoma 
population and significant benefit in a subgroup of patients with advanced-stage disease 
(Ramalingam et al., 2015). Such findings clearly support the utility of the HSP90i, STA9090 to 
combat chemotherapy-refractory disease.  
ACT has shown remarkable clinical success for cancer therapy in the setting of 
hematopoietic malignancies, and more recently in the setting of solid forms of cancer, including 
melanoma (Perica et al., 2015). Since a major concern with developing a combination therapy 
integrating chemotherapeutic drugs (genotoxic, HSP90i) reflects possible negative impact of this 
drug class on the patient’s endogenous immune system. To avoid this, we hypothesized that one 
should apply lower doses of anti-cancer drugs in concert with autologous ACT using CD8+ T 
cells primed against DNA-RP-derived epitopes.  
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The hypothesis for this study was that HSP90i can conditionally sensitize melanoma cells 
to the tumoricidal action of chemotherapy as well as CD8+ T cells reactive against MHC class I-
presented peptides derived from tumor cell overexpressed DNA-RP (intrinsic or after treatment 
with TMZ) that constitute HSP90 client proteins. Our belief was that HSP90i could conditionally 
(and transiently) upregulate the stoichiometry of a pool of HSP90 client protein-derived peptides 
presented in the global “repertoire” of MHC class I/peptide complexes presented on the tumor 
cell surface, allowing for improved recognition and cytotoxicity mediated by specific CD8+ T 
effector cells. No studies have thus far focused on the ability of HSP90i to conditionally increase 
the degradation and subsequent presentation of DNA-RP-derived peptides in MHC class I 
complexes for recognition by the immune system in vivo. The results of our work have potential 
to shape the design and implementation of novel combination chemoimmunotherapies for a 
broad range of patients with cancer, including those afflicted with melanoma.  
We wanted to first characterize the expression of DNA repair client proteins by 
melanoma cells and determine the anti-melanoma efficacy of combined chemotherapy +/- 
HSP90i. We chose Temozolomide (TMZ) as a preferred chemotherapy drug as it is commonly 
used for both melanoma and glioblastoma, with a known capacity to cross the blood-brain barrier 
(Quirt et al., 2007), making it theoretically useful in the context of treating melanoma metastases 
that commonly traffic to the brain, where they are fatal. Since STA9090 has shown promising 
results when applied in combination with Docetaxel in vivo (Ying et al., 2012) and is actively 
being evaluated in the clinic, this 2nd generation drug was an obvious choice as the preferred 
HSP90i for this translational research.  
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Our initial studies reinforced the inability of TMZ alone to promote melanoma apoptosis, 
but that when combined with the HSP90i STA9090, tumor cell sensitization to TMZ-induced 
apoptosis was increased by a factor of 5.   
From studies performed by the Kauffmann group, it was evident that DNA-RP become 
overexpressed during the transition from primary-to-metastatic melanoma, in association with 
melanoma resistance to conventional chemo- and radiotherapies (Kauffmann et al., 2008). In 
order to identify the cell cycle phase involved in melanoma resistance to TMZ, we investigated 
cell cycle transition in the absence or presence of TMZ +/- STA9090. Our results showed that 
TMZ induces enhanced G2/M arrest that may be reversed by cotreatment with STA9090. Based 
on this finding, we selected for further analysis several key proteins involved in the HR and 
NHEJ repair pathways that are HSP90 clients. Amongst the considered DNA-RP, ATR, PRKDC, 
MRE11, NBN, RAD50 and RAD51 were identified as overexpressed melanoma proteins in the 
Kauffmann study. To ensure that these proteins were in fact overexpressed in the specific 
melanoma cell lines that we selected for modeling purposes (i.e., murine melanomas B16 and 
BPR; human metastatic melanoma cell lines, Mel526 and Mel624), we analyzed lysates of the 
cultured melanoma cell lines using SDS-PAGE and Western Blotting for specific DNA-RP 
expression levels. We detected all of these DNA-RP in each of the melanoma cell lines, with the 
exception of PRKDC in Mel526 and RAD51 in Mel624.  
Furthermore, we noted that TMZ promoted increased expression of DNA-RP (i.e., 
RAD50, BRCA2, NBN, ATR) and HSP90 proteins in melanoma cells in vitro and in vivo. 
Subsequent quantitative RT-PCR analysis suggested that while tumor cell transcription of 
HSP90 was increased after TMZ treatment, levels of mRNA encoding DNA-RP were not 
augmented (with the possible exception of PRKDC) by drug treatment. This result is consistent 
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with a mechanism in which TMZ-induced transcriptional activation of HSP90 leads to enhanced 
post-translational stabilization and accumulation of DNA-RP client proteins in treated tumor 
cells. 
This suggested that DNA-RP overexpression in TMZ-treated melanomas could be 
antagonized by HSP90i. To determine the effect HSP90i DNA repair protein expression levels in 
this setting, we cultured melanoma cells in the presence of HSP90i NVP-AUY922 and STA9090 
after the cells had been preconditioned with TMZ. Based on Western Blotting analyses, we 
determined that both HSP90i promoted the degradation of DNA-RPs. In extended studies, we 
also assessed melanoma expression of the DNA-RP RAD51 after radiation. Similar to the impact 
of TMZ, we observed increased RAD51 protein expression after radiation, with the accumulated 
protein then degraded upon subsequent treatment of the tumor cells with HSP90i NVP-AUY922.  
From an immunologic perspective, the degradation of these DNA-RP is of interest since 
this process is mediated in the tumor cytosol by the 26S proteasome, a multi-catalytic machine 
responsible for generating small peptides that ultimately become “presented” in MHC class I 
complexes on the tumor cell surface as “barcodes” for antigen-specific CD8+ T cell recognition. 
To confirm this operational paradigm, we treated the murine B16 and human Mel526 melanoma 
cell lines in vitro with TMZ +/- STA9090 +/- MG132 (a proteasome inhibitor). Although this 
system has not yet been optimized, we observed the trend that STA9090-induced degradation of 
DNA-RP previously upregulated in melanoma cells by TMZ was at least partially prevented by 
MG132.  It is important to note that these cell lines are polyclonal and exhibit genetic and 
phenotypic heterogeneity, hence it might be expected that not all proteins under analysis behaved 
in a concerted manner. For example, in B16 melanoma cells, RAD50 was not overexpressed 
when treated with TMZ, NBN was not protected from HSP90i-induced degradation by MG132. 
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In human Mel526 cells, expression of MRE11 protein was upregulated by TMZ, but not 
subsequently induced to degrade by STA9090 treatment. Such variability in the fate of individual 
DNA-RP in the face of these drug treatments reinforces the need to consider the broader impact 
of the combination therapy on the general class of DNA-RP proteins that represent HSP90 
clients across a heterogeneous population of tumor cells.   
Since HSP90i promoted the degradation of several of the identified DNA-RP in a 
proteasome-dependent manner, we next wanted to investigate the ramifications of such 
treatments on tumor cell recognition by DNA-RP-specific CD8+ T cells. Since CD8+ T cell 
epitopes in these proteins had not been previously reported in the literature, we used peptide 
binding algorithms to identify candidate epitopes with highest predicted binding affinity score 
for the two forms of MHC class I molecules expressed in C57BL/6 mice (i.e., H-2Kb and H-
2Db). This led to the synthesis of 30 peptides that were then segregated in three pools of 10 
peptides each that were used to vaccinate and boost naïve mice. After three rounds of 
immunization, mice were euthanized and splenic CD8+ T cells analyzed for their ability to 
produce the effector cytokine IFN-γ (quantitated by ELISA) in response to specific peptide 
restimulation in vitro.  From the results of three such experiments, we selected nine DNA-RP-
derived peptides that were most immunogenic (i.e., RAD5158-66 , RAD51212-219  RAD501180-1187, 
RAD50391-399, ATR1390-1397, PRKDC620-628, MRE11109-116, MRE11208-216 NBN273-281) for use in 
combination chemoimmunotherapy studies. 
We determined that CD8+ T cells isolated from mice vaccinated against a pool of these 
nine peptides exhibited increased recognition of B16 cells that had been pre-treated with TMZ + 
HSP90i (versus those treated with either single drug or left untreated). These data suggest that 
even though B16 melanoma cells are resistant to TMZ, the ability of TMZ to augment DNA-RP 
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expression and of HSP90i to convert this overexpressed protein into immunogenic peptides that 
allow for improved recognition by DNA-RP vaccine-induced CD8+ T cells. The ability to 
generate such anti-tumor effector T cells via vaccination also provided us with the opportunity to 
investigate combination chemoimmunotherapy integrating TMZ, HSP90i and DNA-RP-specific 
ACT.  
As discussed in Chapter 3, we observed that in vivo treatment of established B16 
melanoma in C57BL/6 mice with TMZ did not have beneficial effects with regard to the rate of 
tumor progression. As a consequence, we retained TMZ as a baseline treatment for all four 
combination therapy groups in studies discussed in Chapter 4.  After initial treatment of the mice 
with TMZ (to upregulate DNA-RP expression in tumor cells), the animals were randomized, 
with individual groups of mice then treated with: i.) two weekly i.p. doses of STA9090, ii.) two 
weekly doses of i.v. ACT, iii.) two weekly doses of STA9090 (i.p.) and ACT (i.v.), or iv.) PBS 
(i.p.). We observed that melanomas in the group treated with combined TMZ/HSP90i + ACT 
grew more slowly than comparable tumors in mice in any other treatment cohort.  
To further validate the findings from our laboratory that HSP90i enhances T cell 
infiltration into tumor lesions in vivo (Rao et al., 2012), single-cell suspensions from recovered 
spleens and tumor digests were analyzed by flow data, focusing on CD8+ T cell content. We 
noted that the combination TMZ/HSP90i + ACT treatment group contained the highest level of 
CD8+ T cell infiltration in tumors. This finding was also confirmed in immunofluorescence 
microscopy analyses of tumor sections based on a CD3+Tbet+ T cell phenotype (consistent with 
the presence of Type-1 inflammatory/cytotoxic T cells).  Additional studies were performed in 
which we pre-labeled the anti-DNA-RP CD8+ T cells prior to injection into tumor-bearing mice 
with a deep red dye. Subsequent analysis of harvested spleens and tumors revealed no 
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meaningful difference in the frequency of labeled cells in the spleens of treated mice (TMZ + 
ACT vs. TMZ/HSP90i + ACT), while we found that the combination TMZ/HSP90i + ACT had 
over 30-fold more labeled cells in their tumors when compared to the tumors from mice treated 
with TMZ + ACT only. These findings support superior recruitment of therapeutic ACT T cells 
into the tumors of mice receiving TMZ/HSP90i + ACT-based therapy. 
Although this study was performed solely in melanoma models, we predict that the 
preferred combination chemoimmunotherapy that we have identified will prove efficacious 
against other forms of cancer as well. This study also provides a rationale for the use of HSP90i 
STA9090 at a dose (25 mg/kg) far below the MTD in order to enhance therapeutic T cell 
infiltration into tumors, in association with superior anti-tumor efficacy, particularly when used 
in combination with ACT-based immunotherapy approaches. The use of low dose, metronomic 
protocols for administering HSP90i is likely to optimize overall clinical efficacy based on a 
balance between the intrinsic anti-tumor effects of this drug class and its impact on effector vs. 
regulatory immunity in the tumor microenvironment. Future studies will need to refine the dose 
and schedule for optimal therapeutic benefits associated with HSP90i-based (combination) 
therapies.  
A study by Proia and Kaufmann suggests that the combination of weekly-administered 
STA9090 (125 mg/kg) with anti-PD-L1 antibody STI-A1015 promotes superior antitumor 
activity in vivo when compared with either single agent, with similar results was observed in pre-
clinical  B16 melanoma models (Proia & Kaufmann, 2015). Considering the current success of 
immune checkpoint blockade protocols using PD-1 and/or PD-L1 targeted therapies in 
melanoma, it is both logical and important to further analyze: i) how our combination 
chemoimmunotherapy impacts expression of PD-L1 within the TME, and ii.) how this regimen 
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might be further improved in its anti-tumor efficacy by further combination with anti-PD-1 
and/or anti-PD-L1 antagonist antibodies.  As discussed in Chapter 4, combination with effective 
HSP70i may also represent another alternative to HSP90i or they can be used therapeutically in 
combination to minimize compensatory mechanisms of adaptive tumor resistance in vivo.  
The results of our studies may be particularly beneficial to patients who have undergone 
chemotherapy in the past and have developed treatment-associated resistance and disease 
progression. Although our experiments have focused on use of TMZ as a chemotherapeutic agent 
to conditionally upregulate DNA-RP expression in tumors, we also noted similar results for the 
commonly-prescribed anthracycline agent, Doxorubicin. This may expand the generality of our 
findings and assist in the future development of novel combination chemoimmunotherapy 
approaches that will have a significant public health impact. 
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           APPENDIX – ABBREVIATIONS 
17- AAG, 17-N-allylamino-17-demethoxygelandamycin
17- DMAG, 17- Dimethylaminoethylamino-17-demethoxygelandamycin
Abs, Antibodies 
ACT, Adoptive Cell Therapy 
Ad-IL12, Adenovirus induced Interleukin 12 
ADP, Adenosine diphosphate 
AHA1, Activator of Heat Shock Protein ATPase 1 
AIF, Apoptosis-Inducing Factor 
AKT1, Also known as PKB – Protein Kinase B 
ANOVA, Analysis of Variance 
APC, Antigen Presenting Cells 
ASK1, Apoptosis Signal-Regulating Kinase 1 
ATCC, American Type Culture Collection 
ATM. Ataxia Telangiectasia Mutated serine-protein kinase 
ATP, Adenosine Triphosphate 
ATR, Ataxia Telangiectasia and Rad3 related protein kinase 
BER, Base Excision Repair 
BRAF, B-Raf proto-oncogene 
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BRCA1, breast cancer 1 
BRCA2, breast cancer 2 
CAR, Chimeric Antigen Receptor 
CD, Cluster of Differentiation 
CDC37, Cell Division Cycle 37   
CHEK1, Checkpoint Kinase 1 
CHEK2, Checkpoint Kinase 2 
CM, Complete Media 
CML, Chronic Myeloid Leukemia 
CNS, Central Nervous System 
CRT, Chemo Radio Therapy 
CT, Chemotherapy 
CTL, Cytotoxic T Lymphocyte 
CTAG1B, a cancer testis antigen  
CTLA4, Cytotoxic T Lymphocyte Antigen 4 
CYP40, Cyclophilin 40 
CYPD, Cyclophilin D 
DAB, Dabrafenib 
DAPI, 4’,6 –Diamidino – 2- Phenylindole 
DC, Dendritic Cells 
DMSO – Dimethyl Sulfoxide 
DNA, DeoxyriboNucleic Acid 
DNA-RP, DNA Repair Protein 
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DOX, Doxorubicin 
DSB, Double Strand Break 
ER, Endoplasmic Reticulum 
ERBB2, Also known as Her2/Neu  
ERCC, Excision Repair Cross-Completion 
ERK, Extracellular Signal-Regulated Kinase 
FANCD2, Fanconi Anemia Completion Group D2 
FDA, Food & Drug Administration 
Fmoc, Fluorenylmethyloxycarbonyl chloride 
GA, Geldanamycin 
GBM, Glioblastoma 
Gp100, Glycoprotein 100 
GRP, Glucose Regulated Protein 
Gy, Gray (unit of radiation) 
H, Hours 
H2AX, H2A histone family member X 
H-2Db/ H-2Kb, Murine class I molecules in the H-2 haplotype mouse
HDACi, Histone deacetylase inhibitor 
Her2, Human Epidermal Growth Factor Receptor 2, aka ERBB2 
HIP, Carboxyl-terminus of HSP70 interacting protein 
HLA, Human Leukocyte Antigen 
HOP, HSP70/HSP90 Organizing Protein 
Hprt, Hypoxanthine Phosphoribosyltransferase  
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HR, Homologous Recombination 
HRP, Horeradish Peroxidase  
HSF1, Heat Shock Factor Protein 1 
HSP, Heat Shock Protein 
HSP90i, HSP90 inhibitor 
i.p., Intraperitoneal
i.v., Intravenous
IACUC, Institutional Animal Care and Use Committee 
IARC, International Agency for Research Cancer 
IL, Interleukin 
IR, Irradiation 
KIT, KIT Proto-Oncogene Receptor Tyrosine Kinase  
MAPK, Mitogen-Activated Protein Kinase  
MDSC, Myeloid-Derived Suppressor Cell 
MEK, alias for MAP2K (Mitogen Activated Protein Kinase Kinase) 
MHC, Major Histocompatibility complex 
MMR, Mismatch Repair 
MRE11, Meiotic Recombination 11  
MRN, complex of MRE11, RAD50, & Nibrin 
MSH2, Muts Homolog 2 
NBN, Nibrin  
NER, Nucleotide Excision Repair 
NHEJ, Non-Homologous End Joining 
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NK, Natural Killer Cells 
NMA, Non-Myeloablative 
NSCLC, Non-Small Cell Lung Cancer 
NVP-AUY922, an HSP90 inhibitor also known as Luminespib 
ORR, Objective Rate Response 
PBMC, Peripheral Blood Mononuclear Cell 
PCNA, Proliferating Cell Nuclear Antigen 
PD-1, Programmed Cell Death 1 receptor 
PDGFRs, Platelet-derived Growth Factor Receptors 
PD-L1, Programmed Cell Death 1 receptor Ligand 1 
PI, Propidium Iodide 
PI3K, Phosphoinositide 3-kinase 
PMEL, Premelanosome protein 
PVDF, Polyvinylidene flluoride 
RAF, Raf-1 proto-oncogene, serine/threonine kinase 
RAS, Viral Oncogene Homolog family of related proteins 
REP, Rapid Expansion Protocol 
rmGM-CSF, Recombinant Murine Granulocyte/Macrophage Colony-Stimulating Factor 
ROS, Reactive Oxygen Species 
RPA, Replication Protein A 
s.c., Subcutaneous
SSB, Single Strand Break 
STA9090, Small molecule HSP90 inhibitor also known as Ganetespib 
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TAM, Tumor-Associated Macrophages 
TAP, Transporter Associated with antigen processing 
T-bet, Tbox Transcription factor
Tc1, Type-1 CD8+ T 
TCR, T-Cell Receptor 
Teff, T effector cells 
TIL, Tumor-Infiltrating Lymphocyte 
TME, Tumor Microenvironment 
TMZ, Temozolomide 
TNF, Tumor Necrosis Factor  
TP53, tumor (suppressor) protein p53 
TPR, Translocated Promoter Region 
TRAP1, Tumor necrosis factor Receptor-Associated Protein 1 
Treg, Regulatory T cells 
TUNEL, Terminal deoxnucleotidyl transferase dUTP Nick End Labeling 
US, United States 
UT, Untreated 
UV, Ultra Violet 
VEGFRs, Vascular Endothelial Growth Factor Receptors 
XRCC4, X-ray Repair Cross-Complementing protein 4 
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